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PREFACE
The purpose of this dissertation is to define the relationship between the newly
discovered ubiquitin E3 ligase, Breast Cancer Associated Gene 2 (BCA2), and the master
regulator of cellular energy metabolism, AMP-activated protein kinase (AMPK), in a breast
cancer context. Negative regulation of AMPK by BCA2, including the proposed limitation of
metformin use in the treatment of cancer and all that follows in the results section, has never
before been reported. It is my hope that the discoveries made within this body of work provide
new grounds for the basis of developing specific inhibitors of BCA2 for the treatment of breast
cancer that may one day translate into the clinic.
This work is original, except where references are made to previous published works and
was in part funded by the National Cancer Institute – Developmental Therapeutics Program,
1R01CA127258-01, Office of the Vice President for Research (OVPR), DeRoy Testamentary
Foundation and the Thomas C. Rumble pre-doctoral fellowships.
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CHAPTER 1
INTRODUCTION
Breast Cancer
Breast cancer is the most commonly diagnosed cancer type in women, with an estimated
232,340 new invasive cases in 2013 (American Cancer Society, 2013). Following the 2002
study from the Women’s Health Initiative that linked the use of combined estrogen and progestin
for menopausal hormone therapy (MHT) to an increased risk of developing breast cancer, a 7%
decrease in incidence rates was seen and can be attributed to cutbacks in this treatment (Rossouw
et al., 2002). However, the most recent five year data available, from 2005 to 2009, suggests
incidence rates to be fairly steady (American Cancer Society, 2013). As the second most
commonly diagnosed cancer type in women, breast cancer comes in second to lung cancer for
cause of cancer death taking roughly 39,620 fated lives in 2013. Although death rates have
steadily decreased in women over the last 25 years or so, presumably due to a decrease in MHT,
earlier detection, and better treatment options, breast cancer still remains at the top of the list for
both incidence and mortality, indicating a continued need for novel detection methods,
prognostic biomarkers and treatment options. In the clinic it is currently treated locally with
surgery plus/minus radiation and systemically with cytotoxic chemotherapy, hormonal therapy,
immunotherapy and targeted therapy (National Cancer Institute, 2013; Rakha, 2013). Surely
these treatment options provide many survival benefits to patients, but they also include a large
category of adverse side effects related to toxicity that significantly affect the patient’s quality of
life. The clinical decision of which treatment course to pursue is based on several tumor
descriptive factors: histopathology (ductal or lobular), grade (tumor cell appearance vs. normal
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breast), stage (TNM system), and receptor status (estrogen receptor (ER), progesterone receptor
(PR) and HER2) (National Cancer Institute, 2013; Rakha, 2013).

Although cytotoxic

chemotherapy is still the most commonly chosen route, targeted therapy has become a major
component of many treatment regimens. Drugs like tamoxifen and Herceptin for the treatment
of ER and HER2 positive cases, respectively, has not only revolutionized the management of this
group of cancers, but also the outlook for future application of novel targeted therapies in the
treatment of breast cancer.

Ubiquitin-Proteasome System
The ubiquitin-proteasome system (UP-S) is responsible for about 80% of all protein
degradation in the cell, with the lysosome being accountable for the other 20% (Ciechanover et
al., 2000; de Duve, 2005). Proteasome degradation is essential for the progression of all normal
cell processes as it removes misfolded, damaged, and toxic proteins that may otherwise be
harmful to the cell. However, a look back through history tells us that the proteasome was not
always accepted in this role. In the early 1950s the lysosome was discovered as a proteolytic
organelle and the proteases within this compartment were thought to be primarily responsible for
all intracellular proteolysis (De Duve et al., 1955). Then, in the 1980s, reports of an entirely new
and non-lysosomal protein degradation system surfaced. The accumulated evidence suggested
this system to be very specific and dependent on a novel post-translational phenomenon termed
polyubiquitination. The discovery of the UP-S (figure 1) is accredited to Aaron Ciechanover,
Avram Hershko and Irwin Rose; their work was acknowledged with the 2004 Nobel Prize in
Chemistry.
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Figure 1. The Ubiquitin Proteasome System
Ubiquitin is activated by the ubiquitin activating enzyme (E1) and requires ATP. It is then
transferred to the ubiquitin conjugating enzyme (E2). In the presence of an E3, ubiquitin is
transferred to a specific protein substrate and targeted for degradation by the proteasome. The
protein is chopped into small peptide fragments and the ubiquitin recycled.
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As a large multi-subunit protease, the 26S proteasome was described to contain a ring-shaped
19S regulatory lid and a 20S catalytic core component, further made up of polypeptide subunits
(Arrigo et al., 1988; Gerards et al., 1998; Hoeller and Dikic, 2009). The 20S core is composed of
two identical outer and inner rings each having seven α and seven β subunits, respectively;
together they are arranged in a stacked cylindrical structure with a narrow pore. It is through this
pore that specific protein substrates pass before they are ultimately degraded (Gerards et al.,
1998) . The proteasome is ubiquitously expressed and can account for up to 1% of total protein
content in the cell (Arrigo et al., 1988; Ciechanover et al., 2000; Gerards et al., 1998).
Furthermore, it is essential for many key cell regulatory mechanisms such as, cell cycle,
transcription, DNA repair and protein transport. It is no surprise that modulating its function
seemed to at first be an intangible strategy when considering novel molecular targets in the
treatment of cancer (Glickman, 2000; Goldberg et al., 1995; Groll et al., 2009). However,
proteasome inhibitors have been developed, have proven to be relatively cancer cell-specific and
as a result, in the last decade, have translated into the clinic. Bortezomib, the first FDA approved
proteasome inhibiting anticancer agent used for the treatment of relapsed multiple myeloma and
mantle cell lymphoma, is the field’s prototype. Carfilzomib, a second generation product, was
FDA approved (2003) for patients with multiple myeloma progression while on, or after
treatment with, bortezomib and an immunomodulatory agent.

Furthermore, proteasome

inhibition has been shown to be a valuable strategy in the sensitization of cancer cells to effects
of traditional chemotherapies and radiation (Buac et al., 2012). While bortezomib has achieved
some success in the treatment of hematological malignancies, it has produced only
disappointment in solid tumor cases. But if we continue to look within the confines of the UP-S,
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we find a rich supply of other promising molecular drug targets just upstream of the proteasome.
The remarkable level of specificity achieved by this system after all, is accredited to the series of
events that actually precede the proteasome’s activity, the process of polyubiquitination (Burger
and Seth, 2004; Glickman and Ciechanover, 2002; Nalepa and Wade Harper, 2003; Weissman,
2001).
Ubiquitination is a sequence of ATP-driven events that involves the activation and transfer of
ubiquitin to particular protein substrates (figure 1); it is dependent on three different groups of
enzymes: the ubiquitin-activating enzyme(s) E1, ubiquitin-conjugating enzymes E2, and the
ubiquitin E3 ligases, which are present in a hierarchal nature. For a while only one E1 enzyme
was known to exist, however there are now reports of at least one other E1 in the human genome
and an estimated 55 E2 conjugating enzymes and 500 E3 ligases. E1 mediates the ATPdependent transfer of ubiquitin to an E2 and the latter either directly transfers it to the substrate,
in the presence of an E3, or to an E3 that then ubiquitinates the specific protein substrate, which
may be itself (autoubiquitination) (Handley-Gearhart et al., 1994; Jin et al., 2007; Nandi et al.,
2006). Generally speaking, polyubiquitinated proteins at the lysine 48 residue are degraded by
the 26S proteasome. Ubiquitin chains can also form on alternative lysine residues, like lysine 63
and other non-traditional sites, in which case regulatory functions are carried out such as, protein
transport, regulation of DNA repair and translation (Kimura and Tanaka, 2010; Komander and
Rape, 2012; Mukhopadhyay and Riezman, 2007; Pickart and Eddins, 2004). Efficient and
targeted ubiquitination of the UP-S therefore depends on the E3 ligases and an imbalance in their
activity and expression has been extensively reported to play a role in the pathogenesis of breast
cancer (Burger et al., 2006; Chen et al., 2006a; Ohta and Fukuda, 2004; Sun, 2006). E3 ligases
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are typically classified according to structure domain homology, of which the HECT
(Homologous to E6-associated protein C Terminus)-type and adaptor type are possible (figure
2). The adaptor type E3s can further be broken down into those that contain a RING (Really
Interesting New Gene)-finger, a U-box or PHD domain (Ardley and Robinson, 2005; Dikic and
Robertson, 2012; Hatakeyama and Nakayama, 2003; Metzger et al., 2012). While the PHD and
U-box E3s are similar in structure to the RING-finger E3 ligases, in a breast cancer context, the
RING-finger E3s are the most well characterized of the group.
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Figure 2. Classification of ubiquitin E3 ligases
In total, about 500 E3 ligase enzymes exist in the human genome. They are broken down into
either the HECT type or Adaptor type. The latter is further classified by domain homology into
the RING, U-Box or PHD groups. Also shown is a cross-section of the RING CH or H2 domain,
complexing two zinc ions critical for E3 ligase activity.
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RING-finger containing E3s make up about 230 of the known 500 genes and are classified as
either RING-HC-type (C3HC4) or RING-H2-type (C3H2C3), with the cysteine (C) and
histidines (H) representing zinc binding residues that form a sort of cross-brace structure in
which two zinc ions are complexed within (figure 2). The RING domain can either be a part of a
multisubunit complex, such as the SCF (Skp1/Cullin-1/F-box) protein, or be simply monomeric,
like Mdm2 (Mouse double minute 2 homolog) (Deshaies and Joazeiro, 2009). The RING
domain is critical for E3 ligase activity and first became the target for inhibition by a series of
zinc ejecting compounds first developed by the National Cancer Institute (NCI) in an effort to
uncover new drugs for the treatment of human immunodeficiency virus 1 (HIV-1).

The

nucleocapsid protein, p7, is essential to the development of the virus and encompasses a highly
conserved cysteine/histidine-rich retroviral Zn-finger domain, from which zinc could be ejected
and prevent its function (Rice et al., 1993; Rice et al., 1997b).
RING-finger E3 ligases are typically tightly controlled, but tend to have a deviant nature in a
breast cancer setting as they regulate the turnover of key tumor suppressor proteins and
oncogenic receptor tyrosine kinases. For example, the E3 ligases that degrade tumor suppressor
proteins p53, p27, and 14-3-3σ (Mdm2/Hdm2, SCF and Efp respectively), are often
overexpressed; and those that degrade oncogenic receptor tyrosine kinases, like c-Cbl, are
deregulated (Burger et al., 2006; Dong et al., 2003; Fang et al., 2000; Honda et al., 1997; Jia and
Sun, 2011; Kubbutat et al., 1997; Miura-Shimura et al., 2003; Talis et al., 1998). That RINGfinger E3 ligases are a class of “druggable” anti-cancer targets has also been reported. Most
notably, trastuzumab (Herceptin) has been reported to induce c-Cbl mediated degradation of
HER2. Efforts placed on inhibiting Mdm2 activity have culminated in the development of some
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small molecule inhibitors that either directly inhibit its activity or interaction (Nutlin) with p53
(Klapper et al., 2000; Secchiero et al., 2011). These examples provide evidence of the fact that
the door is open to E3 ligase therapeutic intervention in cancer. Along these lines, the optimal
cancer drug target should: i.) be minimally expressed in normal cells, but overexpressed in
cancer cells and associated with poor prognosis, ii.) play an essential role in maintaining and/or
promoting the cancer cell phenotype, iii) be an enzyme or cell surface molecule that can be
easily targeted, iv.) result in either inhibition of cell growth or promotion of cell death upon
inhibition of its activity and/or expression (Gashaw et al., 2011). The overall goal corresponding
to the above criteria is to achieve a maximal therapeutic effect to toxicity ratio. One such target
that meets most of these precedents is also a RING-finger ubiquitin E3 ligase, termed BCA2
(Breast Cancer Associated Gene 2).

BCA2
The partial BCA2 cDNA sequence was initially called Di12 and cloned from a subtractive
hybridization library, derived from Hs578T and Hs578Bst matched invasive and normal breast
cell line mRNAs in the laboratory of Dr. Arun Seth by Dr. Angelika Burger at the University of
Toronto, ON (Burger et al., 2003). The full length BCA2 gene was later cloned from the human
breast cancer cell line MDA MB 468 and after the release of the complete human genome
sequence in the year 2000, was identified to be an exact match of the hypothetical zinc finger
protein 364 (Genebank accession no. NM_014455). BCA2 maps to chromosome one (1q21.2),
has
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exons,

mRNA

is

1927

base

pairs

long,

and

is

synonymous

to

T3A12/ZNF364/Rabring7(Burger et al., 2005). The BCA2 protein is a RING-H2-type ubiquitin

10

E3 ligase, contains an AKT/14-3-3 binding site, as well as a zinc-finger and RING-finger domain
near its C-terminus (figure 3).

Figure 3. Schematic of BCA2 (T3A12/ZNF364/Rabring7)
Shown are the 9 exons of BCA2 and its three respective domains. An N-terminal zinc finger
domain and a C-terminal RING-finger domain are shown as well as the AKT
phosphorylation site.
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Both the Zn-finger (BZF domain) and RING finger domains bind zinc ions and are capable of
binding ubiquitin, however the RING domain is the protein-interacting domain, which is also
required for its autoubiquitination activity (Amemiya et al., 2008; Burger et al., 2005). The
unique ability of E3 ubiquitin ligases to autoubiquitinate made it possible to identify BCA2
without the knowledge of its substrates. An initial yeast two-hybrid screen performed in the Seth
lab identified several potential candidates, among which several have been confirmed as binding
partners of BCA2 and include: ubiquitin, Rab7, UBC9, 14-3-3σ, tethrin, and hHR23a. However,
none of which have been confirmed as BCA2 substrates (Bacopulos et al., 2012; Miyakawa et
al., 2009). Only recently has the cell cycle progression regulator, p21, been identified as its first
substrate (Wang et al., 2013). This may in part explain how BCA2 contributes to breast cancer
cell proliferation, at least in the cell lines studied by Wang et al. In addition, members of the
UbcH5 group of E2 conjugating enzymes were found to be active, and be required for, BCA2
ubiquitination, with UbcH5b being most significant (Amemiya et al., 2008). Other E2 enzyme
contributors are also likely. Ubiquitination of proteins occurs on lysine residues and BCA2
contains six, present in twos. One set is located near the N- terminus, another near the COOH
terminus and the final in the middle portions of the protein. The lysine residues determined to be
responsible for its ubiquitination are K26 and K32, located in its BZF domain at the N-terminus,
as mutations in both of these residues was found to be required for a complete loss of BCA2
ubiquitination (Amemiya et al., 2008).
Evidence continues to accumulate that ubiquitin ligases influence the development of
cancer, particularly due to their regulation of the majority of proteins in the cell including,
growth factors, hormones and those controlling cell death or survival decisions. A breast tissue
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microarray taken from the Henrietta-Banting Breast Cancer Collection (HBBCC) (Sunnybrook
Health Sciences Centre, Toronto) revealed overexpression of BCA2 in more than half of the 945
invasive samples, compared to normal tissues. This demonstrated that this novel E3 ligase must
have a distinct role in breast cancer (Burger et al., 2005). Furthermore, BCA2 has been linked to
breast cancer cell proliferation in vitro, and correlates with patient regional reoccurrence history,
making it a good target for therapeutic intervention (Burger et al., 2005). The BCA2 protein is
localized to both the nucleus and cytoplasm of breast tumor cell lines, and the BCA2 promoter
was recently shown to be estrogen responsive (Kona et al., 2012). The function of cytoplasmic
BCA2 remains to be determined, although one can postulate that the action of this form may
correspond to its endemic role, as any BCA2 found in normal tissue primarily localizes to the
cytoplasm.

Much of what is known and published on BCA2 contributes greatly to our

understanding of how this protein is regulated. However its downstream targets, of which only
p21 has thus far been confirmed a substrate, would provide the substantial evidence required to
directly link its expression and activity to overall cancer cell survival. This work provides new
evidence of the role BCA2 plays in the regulation of cellular metabolism; by negatively affecting
AMP-kinase activity, thereby promoting breast cancer cell growth and compromising the effect
of the now popularly studied AMP-kinase activator, metformin (Buac et al., 2013). Although
AMP-kinase is not the direct target of BCA2 E3 ligase activity, TiO2 phosphopeptide enrichment
followed by mass spectrometry, before and after BCA2 knockdown in breast cancer cells, has
revealed several promising targets in this regard. Furthermore, the characterization of BCA2
protein expression patterns, localization and cell cycle dependence is further explored within this
dissertation and has even been extended to prostate cancer cells. All of this work amounts to one
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supporting conclusion: BCA2 is not only a novel target for therapeutic intervention, but may be a
valid biomarker to better predict which patients will respond to particular cancer prevention
and/or treatment modalities.
As previously mentioned, the use of zinc-ejecting compounds for the inactivation of zincfinger/RING-finger containing proteins has widely been reported and such agents comprise three
major classes: disulfides, azoics, and nitroso aromatics (Beerheide et al., 1999; Burger and Seth,
2004; Nash and Rice, 1998). Chemical inhibition of BCA2 enzymatic activity has been reported
and exploring such use would not only minimize the dependence on siRNA transfections to
study its cellular functions, but also potentially provide new therapeutic options (Brahemi et al.,
2010). After an initial screen of compounds from the NCI Developmental Therapeutics Program
Central Drug Repository, disulfiram (Antabuse), a known zinc-complexing compound, was
found to inhibit BCA2 autoubiquitination, comparable to that of the genetically induced cysteine
mutations in the Zn2+ complexing RING-H2 domain (Rice et al., 1997a) .

Disulfiram and Cancer
Disulfiram (DSF, Antabuse®) (figure 4) has been an FDA approved agent for the treatment
of alcoholism since 1951, but has a coincidental origin of discovery. It was initially developed
by Medicinalco, a Danish drug company, in the later part of the 1940s for the treatment of
parasitic infections.
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Figure 4. Chemical structure of disulfiram (DSF)
The chemical structure of the zinc-ejecting compound, DSF, is depicted.
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However, several employees testing it out on themselves expressed unpleasant hangover-like
side effects, including nausea, vomiting, fatigue, and stomach irritation if combined with alcohol
intake. As an anti-parasitic agent, the thiuram structure of DSF was found to act against the zinc
ions contained within the RING-finger like surface proteins of the Giardia lamblia protozoa
(Nash and Rice, 1998). Another unrelated protein enzyme with zinc binding ability is the
hepatic aldehyde dehydrogenase (ALDH).

ALDH1 is critical for the last step of ethanol

metabolism that results in the conversion of toxic acetaldehyde to acetic acid (Agarwal and
Goedde, 1987; Vallari and Pietruszko, 1982). It is the build-up of acetaldehyde in the blood after
alcohol consumption that is responsible for the undesirable hangover symptoms those Danish
scientists reported. Those DSF associated side effects can now be attributed to the drug’s ability
to irreversibly inhibit ALDH1 activity in the liver, via zinc ejection. Therefore, it certainly
serves its purpose in treating patients with chronic alcohol addictions as its effect is almost
immediate, causing a 5-10 fold increase in acetaldehyde concentration, should you even have
just one drink. DSF is otherwise well tolerated and usually prescribed at an initial dose of 500
mg/day for 1-2 weeks, followed by a maintenance dose of 125-500 mg/day (Johansson, 1992).
That DSF has anticancer activity was reported as early as the 1960s and to date there are
over 200 publications showing DSF activity in various cancer types (Cen et al., 2004; Chen et
al., 2006b; Cvek, 2011; Kona et al., 2011; Lovborg et al., 2006; Wickstrom et al., 2007). Most
notably, in the 1970s Wattenberg published several studies that led to further investigation of
DSF use as a chemopreventative agent, noting that if added to the diet of mice, DSF inhibited
large bowel and forestomach cancers, induced by dimethylhydrazine and benzo[a]pyrene
carcinogens, respectively (Borchert and Wattenberg, 1976; Wattenberg, 1975). During the next
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decade, reports surfaced that DSF, amongst other ALDH inhibitors, could restore sensitivity of
leukemia cell lines to oxazaphosphorines. (Sladek and Landkamer, 1985). In addition, in an in
vivo leukemia mouse model, pretreatment with DSF significantly potentiated the cytotoxic
effects of the alkylating agent, nitrogen mustard (Valeriote and Grates, 1989). Our past in vitro
and in vivo experiments using a MCF7 breast cancer model studying the effect of DSF in
combination with cisplatin indicated a synergistic effect between the two drugs, significantly
enhancing the antitumor activity of cisplatin with combination indices (CI) below 1µM at the
inhibitory concentration 50% (IC50) (Kona et al., 2011). Also impressive are the phase I and II
clinical trial results studying this combination in 10 patients, in which no toxicity to the kidneys
was reported and the antitumor response of cisplatin (at 50-120mg/m2) was not compromised
(Qazi et al., 1988). Patients actually found relief of nausea and vomiting symptoms commonly
associated with cisplatin use, suggesting a protective effect of DSF. These results are also
echoed in another larger clinical trial of 53 patients with cisplatin sensitive malignancies,
however the overall survival benefit of DSF inclusion to standard chemotherapy regimens
remains unclear (Verma et al., 1990).
A plethora of molecular mechanisms exists in the literature to explain DSF’s antitumor
activity in a spectrum of cancer types such as breast, prostate, hepatic and blood, including:
inhibition of NFkB, AP-1, Bcl-2, P-glycoprotein efflux pump (P-gp), and key DNA methylating
enzymes; G1/S phase arrest and upregulation of the tumor suppressor protein, p53, have also
been reported (Lin et al., 2011; Liu et al., 1998; Loo and Clarke, 2000). Furthermore, DSF also
has proteasome inhibition ability, including associated TNFα induced NFκB translocation
inhibition and cytotoxic effects (Lovborg et al., 2006). The desirable antitumor consequences
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found with its use could be achieved at concentrations comparable to that of the clinically
approved proteasome inhibitor, bortezomib, and its cytotoxic effects were attributable to the
initiation of apoptosis as measured by caspase -3/7 activation, nuclear fragmentation and cell
membrane permeability (Lovborg et al., 2006; Wickstrom et al., 2007). The means by which
DSF can inhibit the proteasome is at least in part due to its ability to inhibit the chymotrypsin
(CT)-like activity of the proteasome (Chen et al., 2006b). In this study they show that a DSFcopper complex can inhibit proteasomal activity in cultured breast cancer MDA MB 231 and
MCF10DCIS.com cells, but not in the normal MCF10A. Furthermore, cadmium (Cd)-DSF
complexes were also explored (Li et al., 2008). The results reported also indicate inhibition of
the proteasome and induction of apoptosis via inhibition of CT-like activity in breast cancer
cells. Similar to the DSF-copper complexes, this proteasome inhibition was associated with an
accumulation of ubiquinated proteins and the proteasome substrate p27, leading to apoptosis.
DSF’s metal complexing and proteasome inhibitory qualities were also tested in melanoma cells
where it was found to more potently reduce cyclin A expression and cell proliferation in
combination with copper or zinc than DSF alone (Brar et al., 2004). It also inhibited growth and
angiogenesis in melanomas transplanted in severe combined immunodeficient (SCID) mice,
which was potentiated by zinc supplementation (Brar et al., 2004). Encouragingly, a patient with
stage IV metastatic ocular melanoma achieved clinical remission with its use and remained on
oral zinc gluconate and DSF maintenance for 53 continuous months with few side effects (Brar
et al., 2004). Such promising data have culminated in phase I II and III clinical trials assessing
DSFs antitumor activity in metastatic melanoma and solid tumors of the lung and liver. The
phase I/II trial in metastatic melanoma (NCT00256230) and phase II/III studies in non-small cell
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lung cancer (NCT00312819) have recently been completed and a report of the results is pending.
Furthermore, the phase I study at the Huntsman Cancer Institute in Utah (HCI 26679) is still
ongoing.
Disulfiram and E3 Ligases
As briefly previously mentioned, the critical role of zinc fingers and their development as
potential therapeutic targets was first recognized by the NCI, specifically in the advancement of
novel drugs for the treatment of HIV-1, via targeting the zinc ions in RING-finger E3 ligases
(Rice et al., 1993; Rice et al., 1997b). These efforts produced a series of compounds that
specifically modified the highly conserved cysteine/histidine-rich retroviral Zn-finger domains of
the HIV-1 nucleocapsid protein, p7, by ejection of zinc and therefore inactivation of its essential
activity for virus replication. One such agent, azodicarbonamide, even entered clinical trials
against acquired immunodeficiency syndrome (AIDS), pointing to the translational potential of
drugs with such protein modifying mechanisms (Rice et al., 1997b). Another representative of
this type of drug class with similar capabilities in a cancer setting is 4,4-dithiodimorpholine
(C16). C16 has been shown to remove zinc from zinc-finger domains critical for E6 function,
the HECT-type E3 ligase responsible for the degradation of p53 in cervical cancer. It selectively
reduced cell viability, associated with higher levels of the p53 protein (Beerheide et al., 1999).
Several hundred zinc-fingers and RING-fingers exist in the human genome and thus the concern
for pleiotropic effects is valid, however, the literature suggests that unique primary sequences
and secondary protein structures of RING-finger E3 ligases that depend on zinc for catalytic
activity could be specifically inhibited by such agents discussed herein (Burger, 2009; Deshaies
and Joazeiro, 2009).
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It has been shown that DSF could inhibit recombinant BCA2 and BCA2 expressing cells
specifically in the sub-micromolar range, while the p7 HIV-1 nucleocapsid zinc-ejecting agent,
NSC667089, could not (Beerheide et al., 1999; Brahemi et al., 2010; Burger et al., 2005; Kona et
al., 2011). Furthermore, the TSQ (N-(6-methoxy-8-quinoyl)-p-toulenesulfonamide) zinc release
fluorescence assay using recombinant BCA2 confirmed DSF’s capability of removing zinc ions
from BCA2 (Kona et al., 2011). However, because of the multiple modes of action of DSF,
analogs were designed based on the structural requirements for inhibition of BCA2, with the
hope of increasing selectivity for BCA2 zinc-ejection and have since been tested (Brahemi et al.,
2010). From the structure activity relationship (SAR) analysis, we found that a N(C=S)S-S
motif was required for specific inhibition of BCA2 and notably two DSF analogs, ANFD24 and
DPT001, were found to potently (submicromolar range) inhibit BCA2 autoubiquitination (figure
5) (Brahemi et al., 2010). Based on our SAR analysis, 77 compounds containing the N(C=S)S-S
were received from the NCI and have since been screened. These data are discussed in Chapter
4. Therefore, although DSF can inhibit specific E3 ligases such as BCA2, its chemical structure
elements can also be used as a basis for SAR studies in the identification of more selective E3
ligase inhibitors.
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Figure 5. Chemical structures of DSF analogs
ANFD24 and DPT001 contain the N(C=S)S-S motif (circled) found to be required for inhibition
of BCA2 autoubiquitination and breast cancer cell growth, compared to the inactive D23
compound.
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AMPK and cancer cell metabolism
That cancer cells exhibit an altered metabolism was most notably recognized by Otto
Warburg almost a century ago. He noted their preference of glucose breakdown via glycolysis
over oxidative phosphorylation, even in the presence of oxygen, and in 1956 suggested it to be a
cause of cancer development (Warburg, 1956). However, whether or not this phenomenon is a
cause or symptom has been debatable and only recently has altered cancer cell metabolism been
acknowledged as one of the hallmarks of cancer (Hanahan and Weinberg, 2011). Why would
cancer cells prefer such an inefficient energy producing process when oxidative phosphorylation
may be an available alternative? The tumor cell mitochondria must be defective. But they are
not. In fact recent evidence suggests them to be intact and glucose oxidative phosphorylation to
be functioning normally (Cantor and Sabatini, 2012; Pollak, 2012; Ward and Thompson, 2012).
Yet still, neoplastic cells preferentially choose to undergo vigorous amounts of anaerobic
metabolism. The answer is deeper than the ATP energy produced by either of these processes.
Anaerobic metabolism also provides the necessary biomaterials required for proliferation, and
therefore tumor growth, such as, nucleic acids, lipids and proteins (Cairns et al., 2011; Vander
Heiden et al., 2009). In this way the Warburg effect is complicated far beyond what he initially
described, in that tumor cells are not only capable of reprogramming glucose metabolism, but
also amino acid, lipid and protein breakdown. Also required for the successful reprogramming
of glucose metabolism is the suppression, or re-activation, of key metabolism related genes
and/or proteins. Many oncogenes have been reported to take part in this movement such as,
MYC, KRAS, AKT1, SRC, and BCR-ABL (Cairns et al., 2011; Dang et al., 2009; MunozPinedo et al., 2012; Ying et al., 2012; Yuan and Cantley, 2008).

But it is a key tumor
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suppressive protein, and master regulator of cellular energy homeostasis, that has taken up much
of the limelight in recent years and has become an attractive anti-cancer drug target. It is
adenosine monophosphate-activated protein kinase (AMPK), whose function in normal cells is to
respond, much like the flip of a switch, to drops in the ATP: AMP ratio and thereby restore
cellular energy balance. AMPK is a heterotrimeric enzyme consisting of an α catalytic subunit
and βγ regulatory subunits (figure 6); it was purified and sequenced in 1994 (Woods et al.,
1996).
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Figure 6. Schematic of the heterotrimeric AMPK enzyme.
AMP levels in the cell rise when ATP is low. As a result, AMP binds to the γ subunit leading
to the phosphorylation of the α subunit by an upstream kinase, triggering a conformational
change to activate the enzyme.
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Adding to its structural complexity, various isoforms of each subunit also exist; two α subunits,
two β subunits and three γ subunits with twelve possible combinations that are differentially
expressed and activated across specific tissue types (Carling, 2004). The AMPK α1 and α2
subunits contain approximately 550 amino acid residues and are highly conserved, the β subunits
differ in the first 65 of about 250 residues, but are otherwise also similar (Steinberg and Kemp,
2009). However, the γ subunits vary in length at their NH2 terminal: 331 residues in γ1, 569 in
γ2, and 489 in γ3, but share a conserved approximate 300 residues at the COOH-terminus
(Steinberg and Kemp, 2009). α1β1γ1 is the most widely distributed isoform of AMPK across
various rat tissues, and is the most commonly studied in terms of cancer, while α2β2γ2 is more
abundant in rat skeletal muscle.
Cellular ATP levels are required to be at high concentrations in order to ensure cell
survival (Nelson et al., 2008). A drop in ATP, even by just 10%, is sensed by AMPK due to a
subsequent rise in AMP and direct binding to the cystathionine-β-synthase (CBS) repeat
sequences, positioned within the Bateman domains of AMPK’s γ subunit. Binding of AMP
results in a conformational change in the enzyme, followed by phosphorylation of the  subunit
at Thr172 by upstream kinases, LKB1, CaMKK or Tak1 (Figure 6) (Carling et al., 2008; Hawley
et al., 2003; Woods et al., 2003). Consequently, AMPK activation shuts down processes that
would further consume ATP energy, like the synthesis of fatty acids and cholesterol, and
conversely stimulates energy producing pathways like glucose uptake and fatty acid oxidation.
In this way energy homeostasis is restored before proliferation can occur and consume even
more energy. Therefore, AMPK function can be said to be required for both cell survival and
inhibition of cell growth. Such metabolic regulation of anabolic and catabolic pathways by the
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ratio of adenine nucleotides was first reported by Daniel Atkinson, which he called the
“adenylate charge hypothesis” (Atkinson, 1968). AMPK is perhaps the best example of this
theory in motion, and although the name AMPK is now widely accepted, it was previously
referred to as Acetyl-CoA (ACC) kinase-3, due to its association, direct phosphorylation and
therefore inhibition of ACC, the rate limiting step in fatty acid synthesis (Steinberg and Kemp,
2009). Labeling it as “AMP-activated protein kinase” was first suggested by Munday et al in
1988 and was then adopted in 1989, when 3-hydroxy-3-methyl-glutaryl-CoA reductase
(HMGR), required for cholesterol synthesis, was recognized to be phosphorylated in parallel
with ACC (Munday et al., 1988). In addition to its allosteric activation by rising AMP levels, it
is now known that AMPK can be activated completely independent of this by Ca2+ pathways
mediated by calmodulin-dependent kinase kinase β (CaMKK) (Hawley et al., 2005; Woods et
al., 2005). In addition, AMPK function in the brain also affects whole body metabolism by
increasing one’s food appetite (Andersson et al., 2004; Minokoshi et al., 2004).
Neoplastic cells have a dysregulated metabolism and AMPK protein levels are generally
kept at a minimum in order to ensure their continued anabolic needs and survival. The molecular
mechanisms responsible for the activation of AMPK are becoming increasingly more clear as in
the past 10 years it has received a lot of attention in the cancer research field as a potential drug
target, perhaps owing to the now widely accepted AMPK-activating ability of metformin, an
FDA approved agent and first line treatment for type II diabetes.

The idea of sustained

activation of AMPK, and therefore limited ATP production, is expected to produce a state of
energy homeostasis that would halt energy consuming processes and create an unfavorable
environment for neoplastic cells. While many laboratories report these results, which have been
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recently reviewed (Shackelford and Shaw, 2009), several other groups have also shown that
AMPK activation in certain tumor types may contribute to cancer cell survival via different
mechanisms (Jeon et al., 2012; Park et al., 2009; Phoenix et al., 2009; Rios et al., 2013;
Vazquez-Martin et al., 2009) of which the downstream survival effectors have not yet been
defined.
In an effort to better understand its regulation, the crystal structure of the C-terminal
regions of AMPK’s α1, β2 and full-length γ1 subunits together in a regulatory core have led to
the revelation that the γ1 subunit has four potential AMP CBS binding sites, yet only three of the
four sites were capable of binding nucleotide (Xiao et al., 2007). After some confusion with
conflicting previous reports describing two exchangeable nucleotides bound in phosphorylated
full-length AMPK (Scott et al., 2004), it was resolved that one of the three is bound so tightly
that it does not engage in exchange and therefore would not be picked up in the earlier binding
assays (Kemp et al., 2007). The question of whether the specific binding to each CBS site has
differential effects on the allosteric and regulation of Thr172 phosphorylation, and therefore
activity of AMPK, has the potential to clarify some of this disagreement seen in the literature.
However, although attempts have been made to mutate the aspartic residues within each
respective nucleotide binding site, they have been unsuccessful and therefore the answer to this
question remains to be addressed (Mayer et al., 2011). Along these lines, the structure of
phosphorylated AMPK, whereby its Thr172 containing activation loop makes plenty of contact
with the C-terminal regions of the α and β subunits described above, thereby blocking access to
inactivating phosphatases, is also well characterized (Carling et al., 2011; Xiao et al., 2011).
While these structural studies provide much insight into the key points of AMPK regulation, how
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AMP aids in Thr172 phosphorylation is unknown. From a genetic standpoint, AMPK knockdown
is embryonically lethal; however there is no evidence of germline mutations in any of the AMPK
subunits that would result in a predisposition to cancer (cancergenome.nih.gov/). Furthermore,
somatic mutations are quite rare, less than 3% for any subunit, and they are actually more
frequently amplified in human cancers (cancergenome.nih.gov/). In contrast, germline mutations
in one of its upstream activating kinases, liver kinase B1 (LKB1) are known to be the cause of
Peutz-Jegher Syndrome (PJS), a rare autosomal dominant predisposition to cancer described by
benign intestinal hamartomatous polyps and mucocutaneous pigmentation that put the patient at
an increased risk for developing varying malignant tumor types (Bardeesy et al., 2002; Jishage et
al., 2002; Nakau et al., 2002; Ollila and Makela, 2011). Somatic mutations of LKB1 exist
primarily in lung and cervical cancers, with some epigenetic inactivation reported to occur in
papillary breast cancer (Ollila and Makela, 2011). Therefore, LKB1 is classified as a tumor
suppressor gene. Taken together, AMPK activity would therefore be predicted to decrease in
tumor cells short of functional LKB1, however it is important to note that its activation can occur
independent of LKB1 in a wide array of cancer lines, with high levels seen even in lung cancer
where LKB1 mutations are common (William et al., 2012). A plausible explanation for this
discrepancy is the existence of other upstream kinases, such as CaMKK and Tak1, or unknown
phosphatases, which may have differing roles in different tumor lineages where metabolic
statuses also differ. Also unclear in this regard is to what extent the energy balance restoring
function of AMPK really adds to the tumor suppressive activity of LKB1. Worth noting though,
is that AMPK activation in LKB1-deficient cells may trigger differing downstream consequences
and therefore be insufficient for cancer cell growth inhibition, but rather sufficient for cell
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survival. Conflicting reports adding to the apparent two-fold function of AMPK have indeed
divided the literature in terms of its credibility as an effective anti-tumor drug target (Carling et
al., 2012; Jeon et al., 2012; Li et al., 2012; Liang and Mills, 2013; Zhong et al., 2008).

Controversies surrounding AMPK activation in cancer
The downstream repercussions of AMPK activation in a cancer setting include a
multitude of molecular mechanisms that are both in favor of and in opposition to its use as a
molecular drug target in the treatment of various cancer types. In its favor are reports outlining
AMPK’s ability to inhibit cancer cell growth via direct and/or indirect inhibition of the notorious
mammalian target of rapamycin (mTOR) (Figure 7) (Hahn-Windgassen et al., 2005; Steinberg
and Kemp, 2009). mTOR exists as two complexes, namely mTORC1 and mTORC2; mTORC1
predominantly functions to activate pathways that promote cell growth when nutrient supply is
adequate and not surprisingly, its abrogated activity has been connected to many cancers (Dazert
and Hall, 2011; Zoncu et al., 2011). AMPK can directly phosphorylate the Thr2446 residue of
mTORC1 and/or Ser792 of RAPTOR, resulting in overall inhibition of its activity (Cheng et al.,
2004; Gwinn et al., 2008). Upstream of mTOR is the tuber sclerosis 1/hamartin/tuber sclerosis
2/tuberin (TSC1/TSC2) complex of which TSC2 Ser1345 can also be phosphorylated by AMPK,
thereby indirectly lowering mTORC1 activity (Inoki et al., 2003).
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Figure 7. Simplified schematic of AMPK on the tumor cell signaling map
Receptor tyrosine kinases signal through Akt and mTORC1 to promote cell growth. AMPK has
an opposing function on mTOR in that it inhibits cell growth. The activation of AMPK by
various kinases may have differing overall cellular effects in cancer cells. mTOR feedback
signaling to Akt is also possible. Importantly, receptor tyrosine kinase signaling is often in
abundance in many cancer types and furthermore, many of the proteins shown converged on
common targets in this pathway.
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In this way AMPK is at the center of the merge between cellular energy metabolism and cell
growth signaling pathways. Many cancers also exhibit high levels of fatty acid synthase (FAS)
activity for de novo fatty acid production by and unknown mechanism that is independent of
lipid and hormone levels already present in circulation (Alo et al., 1999; Swinnen et al., 2000).
AMPK has been shown to indirectly inhibit FAS gene expression in the liver by suppression of
sterol regulatory element binding protein 1 (SREBP1) and these results have been reproduced in
LNCap prostate cancer cells treated with the AMPK activator 5-Aminoimidazole-4-carboxamide
ribonucleotide (AICAR) where a reduction of FAS protein was observed (Xiang et al., 2004).
AMPK can also inhibit breast cancer cell growth via inhibition of fatty acid synthesis by
phosphorylation and inhibition of ACC (Chajes et al., 2006). Other reports describe yet other
molecular anti-tumor effects in breast, ovarian, lung, liver and colon cancers such as, but not
limited to, cell cycle arrest at the G1 phase, promotion of an anti-inflammatory phenotype,
phosphorylation and activation of tumor p53 and p27 tumor suppressor proteins, as well as
inhibition of HIF-1α (Isoda et al., 2006; Jones et al., 2005; Motoshima et al., 2006; Sag et al.,
2008; Treins et al., 2006). Interest in the activation of AMPK as a plausible anti-cancer strategy
really took off after reports surfaced (2005) attributing an overall reduction in cancer risk (~30%)
in diabetic patients taking metformin daily to the indirect activation of AMPK, in addition to its
known ability to inhibit gluconeogenesis in the liver (Evans et al., 2005). Since then, thousands
of papers assessing metformin’s anti-cancer properties both in vitro and in vivo have been
published. Phase II and III clinical trials are also underway (Dowling et al., 2012; Pollak, 2012).
The use of metformin has been experimented with in a wide variety of cancer types, but it has
also exposed some not-so-desirable consequences of AMPK activation in a cancer. This has led
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to much controversy in the literature and it is now highly debatable whether or not AMPK is a
friend or foe in the treatment of cancer, with a large amount of work done particularly in breast
cancer. Generally speaking, it is agreeable that metformin works via indirect activation of
AMPK. The mechanism(s) leading up to this event are unclear, but it is believed to be due to
metformin’s ability to inhibit the mitochondrial respiratory chain complex I, thereby disrupting
the ATP: AMP ratio and activating AMPK (Logie et al., 2012; Owen et al., 2000; Turner et al.,
2008). While most of the data to date are in support of AMPK activation by metformin, those
that are not suggest that the benefits of AMPK activation, and metformin protection, may vary
by patient and tumor type. Indeed, a number of studies have reported AMPK activation to
actually promote tumor growth in prostate cancer and that its inhibition, by siRNA, leads to
reduced cell proliferation (Park et al., 2009). Interestingly, these effects could be prevented with
an inhibitor of CaMKKβ (Jung et al., 2009). Others implicate AMPK in increasing glucose
uptake rate and glycolysis, and even in mitosis during times of low nutrient supply by the control
of myosin regulatory light chain (MLC) (de)phosphorylation (Banko et al., 2011; Massie et al.,
2011). Autophagy, the cell’s means of protein and whole organelle disposal and recycling by
way of the lysosome, occurs in times when the cell is desperate for energy and nutrients to meet
its demands. Therefore, one can immediately deduce that AMPK must participate in activating
this mechanism if need be, and the activation of AMPK in various cancer types resulting in
autophagy and cancer cell protection has certainly been published (Hoyer-Hansen et al., 2007;
Kim et al., 2011; Liang et al., 2007; Lum et al., 2005). Furthermore, since AMPK and Akt
signaling converge on mTOR with conflicting effects (Figure 7), and AMPK phosphorylation
being dominant over Akt, that AMPK antagonizes Akt signaling is certainly an enticing
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proposition. While this may be true in the case of TSC2 and FOXO3, which are phosphorylated
by both and at different sites, it may not translate to cellular outcome. AMPK and Akt have
numerous targets outside of the classical TSC2 and FOXO3 that even overlap such as, IRS1,
TBC1D1, TBC1D4, PFKFB2, PFKB2, TSC2, p27Kip1 and often work together in the regulation
of other physio-regulatory mechanisms, particularly bioenergetics and cell viability (Hardie et
al., 2012; Neufeld, 2012; Steinberg and Kemp, 2009; White, 2012). What’s more is that in
glucose deprived conditions, AMPK and Akt are active and actually function to ensure cell
survival, regardless of mTOR cascade shutdown (Inoki et al., 2003; Zhong et al., 2008). Taken
together then, one should proceed with caution when making conclusions in regards to the
complex and intertwined relationship between AMPK and Akt, as also shown in this body of
work.
The function of AMPK in normal cells is indisputable; it is active only to increase
energy demands in times of need, but also hinders cell growth and proliferation by way of
mTOR inhibition.

How cancer cells adapt to weaken this pathway and alter the possible

downstream effects thereof is still not well understood. What is becoming clearer is that the
effects of its activation seem to be tumor and cell type specific. It is possible that nucleotide
binding to one site over the other in the CBS domain, altered upstream kinase expression from
LKB1 to CaMKKβ, or the existence of some other post-translational mechanism could be
important in understanding the apparent switch in signaling and dichotomy in overall effect.
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Motivation and Approach
Post-translational regulation of AMPK is just beginning to be understood. As the master
regulator of cellular metabolism, this field of study has large implications in our understanding
of cancer development, progression, and even occurrence and prevention, as recently nicely
summarized in two review articles (Carling et al., 2012; Zungu et al., 2011). Evidence for
ubiquitination of the catalytic α and regulatory β subunits of AMPK does exist. The E3 ligase,
cidea, is the only identified E3 in this regard to be responsible for the ubiquitination of the
AMPK β subunit in brown fat tissue, resulting in decreased AMPK activity due to proteasomal
degradation (Qi et al., 2008), whereas the α subunit-specific E3 still remains to be discovered.
Furthermore, ubiquitination of the known upstream AMPK activating kinases has been reported
to also decrease AMPK activity (Al-Hakim et al., 2008; Witczak et al., 2008). As the cell’s
primary means of maintaining protein homeostasis, it is not surprising that AMPK activity is also
regulated by the UP-S, which may represent an alternative avenue in the identification of novel
molecular drug targets controlling AMPK activity in cancer.
As a previously identified E3 ligase with tumor promoting characteristics, BCA2 is an
attractive and novel anti-tumor drug target. This dissertation work identifies BCA2 as a negative
regulator of AMPK activity by regulating an event(s) that controls the (de)phosphorylation of the
Thr172 site within the α 1 subunit (see Chapter 3). While this is not a direct interaction, mass
spectrometry data following phosphopeptide enrichment before and after knockdown of BCA2
in breast cancer cells has identified potential BCA2 substrate-targets that may play a role in
AMPK activation in breast cancer (see Chapter 4). Therefore, the overexpression of BCA2 in
breast cancer cells may be one of the previously discussed mechanisms neoplastic cells utilize to
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modify and/or weaken the AMPK pathway to ensure their survival. Furthermore, this work
provides innovative rationale for the use of metformin in select tumor types, or in combination
with a BCA2 inhibitor, as the overexpression of BCA2 may weaken its anti-tumor effect.
Previous DSF SAR related work has led a to collection of drugs from the NCI that possess the
N(C=S)S-S described earlier, which have been assessed for their ability to inhibit cancer cell
proliferation (see chapter 4).

As potential inhibitors of BCA2, their impending use in

combination with metformin may have valuable future therapeutic implications in breast cancer
treatment. Finally, similar results were reproduced in prostate cancer and the characterization of
BCA2 protein expression/localization assessed in a cell-cycle dependent manner in both tumor
types (see Chapter 5).
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CHAPTER 2
MATERIALS AND METHODS
Reagents Anti-BCA2 antibody was purchased from LifeSpan BioSciences, Inc (Seattle, WA).
FLAG (M2) and β-actin antibodies were obtained from Sigma-Aldrich Corp (St. Louis, MO).
Antibodies to phosphorylated AMPK (Thr 172), ACC (Ser 79) and AKT (S473), as well as to
total AMPK, ACC and AKT, were all purchased from Cell Signaling Technologies (Beverly,
MA). Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG and anti-mouse IgG secondary
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). All primary antibodies were
stored at -20ºC and secondary at 4ºC. The AMPK inhibitor Compound C and dimethyl sulfoxide
(DMSO) were purchased from Sigma-Aldrich Corp (St. Louis, MO). AMPK activators,
metformin and AICAR, were obtained from Toronto Research Chemicals Inc (North York, ON)
and Tocris Bioscience (Minneapolis, MN), respectively. The PI3 Kinase inhibitor LY294002
was purchased from Cell Signaling Technologies (Beverly, MA). The stocks of these chemical
reagents were made up as follows: 20 mM Compound C dissolved in DMSO, 1 M metformin in
sterile H2O, 75 mM AICAR in sterile H2O and 10 mM LY294002 in DMSO. All drug stocks
were stored at -20ºC.
Expression Vectors and Constructs The BCA2 amplicon was subcloned into the FLAG-tagged
pCMV-tag2B vector, as previously described (Amemiya et al., 2008; Burger et al., 2005).
Mutations in the BCA2 RING domain and predicted AKT phosphorylation site were engineered
in the wild type construct as also previously described (Amemiya et al., 2008). The AMPK alpha
1 catalytic subunit (PRKAA1) pCMV6-XL5 vector construct was purchased from the
TrueClone® Human Collection, OriGene Technologies Inc (Rockville, MD). Bacterial stocks of
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all vector constructs were generated in our laboratory. Once amplified and DNA isolated,
plasmid maxiprep stocks were stored at -20ºC.
Cell Culture Human breast cancer MDA MB 231, MDA MB 468, MCF7 and Hs578t cells,
human prostate cancer LNCap, C42B cell lines, and the human embryonic kidney fibroblast
HEK293T cells were obtained from the American Type Culture Collection (Manassas, VA).
MDA MB 231 and MDA MB 468 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM), and MCF7, Hs578t, LNCap and C4-2B cells in RPMI 1640 (Invitrogen, Carlsbad,
CA) containing 10% FBS (Hyclone from Fisher Scientific, Pittsburgh, PA), 100 µg/ml
streptomycin and 100 units/ml penicillin (Invitrogen, Carlsbad, CA). HEK293T cells were also
grown in DMEM containing 10% Fetal Bovine Serum (FBS), but no antibiotics. Cells were
passaged routinely and maintained at 37°C and 5% CO2.
Serum starvation Exponentially growing MDA MB 231, MCF7, LNCaP or C42B cells were
plated at 80% confluency in 100 mm dishes and allowed to adhere overnight. The next day,
media containing 1% FBS was added in place of the 10% and cells were serum starved for 72 to
96 hours. Changing the media back to 10% for 24 to 48 hours synchronized the cells into S
phase of the cell cycle. Drug treatment(s) were performed for the additional time and
concentration indicated in each figure during the respective phase of the cycle.
Transfection (i) Transfection using AMPKα and BCA2 wt and mt constructs (created by sitedirected mutagenesis) (Amemiya et al., 2008). Breast cancer or fibroblast cells were plated in
100-mm dishes at 80% confluency and allowed to settle overnight. A fresh complete medium
change, devoid of antibiotics, was given 2 hours prior to transfection.

For transfection
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experiments using MDA MB 231 cells, 1-3 µg of FLAG-BCA2, wild-type (wt), S132/S133
mutant (mt) (serine 132 and 133 to alanine) or RING (cysteine 228 and 231 to alanine)
(Amemiya et al., 2008; Bacopulos et al., 2012) mt vector DNA was transfected using the
Lipofectamine® LTX reagent according to the manufacturer’s protocol (Invitrogen, Carlsbad,
CA), with pCMV-tag2B empty vector used as a control. Following a 48 hour incubation period,
cells were treated as indicated, harvested and lysed for Western blot analysis. For co-transfection
experiments, 2.5 µg of FLAG-BCA2 wt, S132/S133 or RING mt and 2.5 µg of AMPKα vector
DNA were co-transfected into HEK293T cells using the FuGENE® HD transfection reagent and
protocol (Promega, Madison, WI), with pCMV-tag2B empty vector co-transfection with
AMPKα as a control. For co-transfection experiments studying the concentration-dependent
effects of wt or mt BCA2 on AMPKα, the AMPKα DNA concentration was held constant at 1
µg, while that of BCA2 ranged from 1-5 µg. After 48 hours, cells were treated as indicated,
harvested and lysed for analysis by Western blotting. (ii) Transfection using BCA2 specific small
interfering RNA. The custom designed small interfering RNA (siRNA) duplexes were purchased
from

Qiagen

(Valencia,

CA)

r(CGUCUGAAUAGAAUUAAUU)dTdT,

[BCA2

siRNA

duplex
antisense

2:

sense

=
=

r(AAUUAAUUCUAUUCAGACG)dGdG] and dissolved in siRNA suspension buffer to yield a
stock of 20 µmol/L, stored at -20ºC. Non-silencing control siRNA was used as a negative control
and RNAiFect (Qiagen) as the transfection reagent. Experiments were carried out in 6-well
plates following the manufacturer’s protocol. The siRNA transfection incubation period lasted
72 hours, after which cells were treated accordingly, harvested, lysed and analyzed by Western
blotting.
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Western Blotting Cells were transfected, drug treated, or both, and then harvested. Cell lysates
(30-40 µg) were mixed with 3X sodium dodecyl sulfate (SDS) buffer, boiled for 5 minutes and
analyzed by SDS-polyacrylamide gel electrophoresis using 4-20% tris-glycine gradient gels
(Invitrogen, Carlsbad, CA), and then transferred to polyvinylidene difluoride (PVDF)
membranes (Millipore, Billerica, MA) and blocked in 5% milk powder in TBST for 1 hour at
room temperature. The primary antibodies were diluted in blocking buffer (phosphorylated
antibodies at 1:500 and all remaining at 1:1000) and incubated overnight at 4°C. Membranes
were washed in TBS-Tween 20 (0.2%) and incubated with species-specific secondary antibodies
conjugated to HRP (1:5000) for 1 hour at room temperature. Signals were developed using the
mobilon western chemiluminescent HRP substrate (Millipore, Billerica, MA) and the
FOTO/Analyst® Luminary/FX® Systems Flexible chemiluminescent and fluorescent imagining
workstation (Fotodyne, Hartland, WI). Densitometry analysis was done using ImageJ software
and relative intensity calculated as a percentage of the control.
MTT Assay (i) siRNA: breast cancer MDA MB 231, MDA MB 468 and Hs578t cells were
grown under standard conditions as described above and seeded in 96 well plates (20 000 cells
per well) and allowed to adhere for 24 hrs. BCA2 siRNA (0.75 µg) or non-silencing scrambled
control (0.75 µg) was added for a period of 72 hrs after which metformin was added in
concentrations ranging from 5-30 mM for 24 hrs. (ii) DSF analogs: breast cancer MDA MB 231
and MCF7 cells were seeded in 96 well plates (1 000 cells per well) and allowed to adhere for 24
hrs. DSF analog was added in increasing concentrations (0.01 to 10 µM) for a period of 5 days.
Cell proliferation in either case was determined by addition of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazoliumbromide (MTT) (Invitrogen, Carlsbad, CA). The conversion of MTT to
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purple formazan by viable cells was measured using a Wallac Victor3 1420 multilabel plate
counter (550 nm) and analyzed in Microsoft Excel. Growth curves were generated as percent of
the control and statistical analysis as described below.
Colony Formation Assay An agar concentration of 0.75% in DMEM medium, containing 10%
FBS and 100 µg/ml streptomycin and 100 units/ml penicillin, was dispensed at 200 µl/well of a
24 well plate to create a base layer and allowed to solidify. 200 µl of MDA MB 231 cells in
0.4% agar were added in the next layer (1000/well) and placed at 4°C for 5 minutes to solidify.
Cells are incubated at 37°C and 5% CO2 overnight after which the respective drugs are added in
a total volume of 200 µl/well and colonies are allowed to form over a period of 5-7 days. Once
the colonies formed iodonitro tetrazolium blue (INT) (2 mg/ml) was added at 100 µl/well and
incubated overnight at 37°C and 5% CO2. Colonies of at least 30 µm in diameter were counted
using the Oxford Optronix GelCountTM automated mammalian cell colony counter and CHARM
algorithm software. Colony-forming ability was determined as a percent of those in the control.
RNA analysis by Real-Time PCR Total RNA was extracted using the RNeasy Mini Kit
(QIAGEN) and was reverse transcribed to complementary DNA (Two Step DNA kit,
Invitrogen). The cDNA was amplified using primer pairs for BCA2 forward, 5′GGGGTCACCAGACTCACACT-3′ and reverse 3′-CAGGAAAAAGGGTGTGGAGA-5′. The
loading control was β-actin, primers: forward 5’-GAGCGCGGCTACAGCTT-3’ and reverse 5’TCCTTAATGTCACGCACGATTT-3’
BCA2 Promoter Luciferase Assay Cells were plated in 24-well plates and co-transfected with
BCA2 promoter–luciferase vector (Switch Gear Genomics) and Renilla vector (Promega) as
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previously described (Kona et al., 2012). After 24 h, cells were treated with 20 mM metformin or
1 mM AICAR for 6 hours. Luciferase activity was measured using the Dual Luciferase Reporter
Assay Kit (Promega) and promoter activity was calculated as relative luciferase units (RLU).
Immunoprecipitation HEK293T cells were co-transfected with AMPKα and FLAG-tagged
BCA2 (as above) and co-immunoprecipitation was performed using 700 µg of protein, FLAGantibody, and the Pierce Classic IP Kit (Thermo Scientific, Rockford IL) as per the
manufacturer’s protocol.
Nuclear/Cytoplasmic Fractionation Treated or non-treated cells were collected and washed
twice with ice cold PBS. The cytoplasm was fractionated using a hypotonic buffer solution (20
mM Tris-HCL pH 7.4, 10mM NaCl and 3mM MgCl2) supplemented with 10% NP40 detergent.
A 10 minute centrifugation at 4°C and 3,000 rpm produced the cytoplasmic fraction
(supernatant). The pellet (nuclear fraction) was resuspended in a cell extraction buffer (100 mM
Tris-HCl pH 7.4, 2 mM Na3VO4, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol,
1 mM ethylene glycol tetraacetic acid (EGTA), 0.1% SDS, 1 mM NaF, 0.5% deoxycholate and
20 mM Na4P2O7); supplemented with 1 mM phenylmethanesulfonylfluoride (PMSF). and
centrifuged for 30 minutes at 4°C and 14,000 rpm. The supernatant (nuclear fraction) was
isolated and all samples were stored at -80°C prior to SDS-PAGE analysis.
Immunofluoresence Cells were fixed to slides with ice cold methanol: acetone (1:1) and
blocked for one hour using 5% BSA in PBS. Staining with BCA2 rabbit polyclonal antibody
(LifeSpan BioSciences, Inc) was done overnight at 4°C followed by rabbit TRITC-labeled
secondary antibody (Sigma Aldrich Croporation) for 1 hour at room temperature. Cells were
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washed with PBS in 5 minute intervals, 5 times, followed by nuclei counterstained with 4’6diamidino-2phenylindole (DAPI) for 5 minutes and then more washes. Photomicrographs were
taken at x63 magnification using a Leica DM4000 microscope and 5.0 Openlab Improvision
software to document the signals.
Proteomics: Database Searching Tandem mass spectra were extracted and charge state
deconvolution and deisotoping were not performed. All MS/MS samples were analyzed using
Mascot (Matrix Science, London, UK; version 2.4.0) and X! Tandem (The GPM, thegpm.org;
version CYCLONE (2010.12.01.1), in the laboratory of Dr. Paul Stemmer, Proteomics Core,
Wayne State University-School of Medicine. Mascot was set up to search the
SwissProt_2013_04 database (selected for Homosapiens, unknown version, 20253 entries)
assuming the digestion enzyme trypsin. X! Tandem was set up to search a subset of the
SwissProt_2013_04 database also assuming trypsin. Mascot and X! Tandem were searched with
a fragment ion mass tolerance of 0.020 Da and a parent ion tolerance of 10.0 PPM.
Carbamidomethyl of cysteine was specified in Mascot and X! Tandem as a fixed modification.
Dehydrated of the n-terminus, glu->pyro-Glu of the n-terminus, ammonia-loss of the N-terminus,
gln->pyro-Glu of the N-terminus, oxidation of methionine, acetyl of the n-terminus and phospho
of serine, threonine and tyrosine were specified in X! Tandem as variable modifications. Glu>pyro-Glu of the N-terminus, gln->pyro-Glu of the n-terminus, oxidation of methionine, acetyl
of the N-terminus and phospho of serine, threonine and tyrosine were specified in Mascot as
variable modifications. (Courtesy of Dr. Paul Stemmer)
Proteomics: Criteria for Protein Identification Scaffold (version Scaffold_4.1.1, Proteome
Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein
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identifications. Identified peptides that were present at greater than 80.0% probability, as per the
Peptide Prophet algorithm, were acknowledged (Keller et al., 2002) with Scaffold delta-mass
correction. Protein identifications were accepted if they could be established at greater than
80.0% probability and contained at least 1 identified peptide. Protein probabilities were assigned
by the Protein Prophet algorithm (Nesvizhskii et al., 2003). Proteins that contained similar
peptides and could not be distinguished based on just MS/MS analysis were grouped according
to the principles of parsimony. Proteins sharing significant peptide evidence were grouped into
clusters. (Courtesy of Dr. Paul Stemmer)
Statistical Analysis Western blot densitometry analysis was performed using ImageJ analysis
software (NIH). All phosphorylated proteins were normalized to corresponding total protein
expression and BCA2 to β-actin. Fold change was calculated based on the vehicle
control/untreated lane and error bars are mean ± SEM for repeated experiments. Statistical
analyses of the MTT and colony formation assays were carried out using an unpaired
parametrical t test with Welch’s correction to compare the means of six observations for each
combination treatment to the single agent condition in both the colony formation and the MTT
assays, followed by one-way ANOVA to compare the combination treatments to single agent
and then to the control. All statistical tests were two-tailed and P < 0.05 was considered to be
statistically significant. GraphPad Prism 6 Software was used.
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CHAPTER 3
RESULTS
Regulation of Metformin Response by Breast Cancer Associated Gene 2 (BCA2)
Adapted from published material in Neoplasia, 2013
Although metformin is currently being assessed in Phase II and III cancer related clinical
trials, the benefit of AMPK activation in vitro and in vivo remains controversial in various cancer
types, due to a need for more detailed mechanistic studies (Dowling et al., 2012; Pollak, 2012).
The data presented in this dissertation show that BCA2 has a negative regulatory effect on the
tumor suppressing, cellular stress sensing kinase, AMPK. On the endogenous level, BCA2
inhibits both basal and inducible levels of AMPK phosphorylation at Thr172 and therefore its
activation. This inhibition was dependent on its E3 ligase specific RING domain and was also
affected by S132/S133 mutations in its predicted Akt phosphorylation site (Amemiya et al.,
2008). In addition, the chemical activation of AMPK by metformin or AICAR also increased
BCA2 and pAkt protein levels, suggesting the presence of a possible cell survival feedback
mechanism. Furthermore, the tumor growth-inhibitory benefit of metformin was significantly
improved once BCA2 was silenced (via siRNA) or destabilized (via PI3/Akt kinase inhibition),
compared to treatment with metformin alone, demonstrating that suppression of BCA2 function
enhances metformin’s anti-cancer efficacy.
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Results
BCA2 is an endogenous inhibitor of AMPK Thr172 phosphorylation and therefore
activation
To study the potential relationship between BCA2 and AMPK involved pathways, the
basal expression of each protein in a panel of four breast cancer cell lines was first assessed (Fig.
8). An inverse relationship of BCA2 to pAMPK1 (Thr172) was observed: those cell lines with
higher levels of BCA2, like MDA MB 468 and Hs578t, had lower pAMPK1 (Thr172) levels
when compared to the other two examined, namely MCF7 and MDA MB 231, which contain
relatively lower amounts of BCA2, but higher levels of pAMPK1 (Thr172) (Fig. 8). It has
previously been reported that BCA2 contains a predicted AKT phosphorylation site and that
AKT-mediated phosphorylation at this site is responsible for stabilization of the BCA2 protein
(Amemiya et al., 2008). Levels of pAkt (S473) indeed correlated positively to BCA2 (Fig. 8).
These data provided grounds to further investigate the inverse relationship between BCA2 and
pAMPK, with the hypothesis that BCA2 may be an endogenous inhibitor of AMPK activation in
breast cancer cells.
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Figure 8. The assessment of basal protein expression levels in the four indicated human
breast cancer cell lines.
Exponentially growing cells were lysed for Western blotting analysis with specific
antibodies to BCA2, pAMPK (Thr172), total AMPKa1, pAKT (S473), total AKT and β-actin
(loading control).
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To provide direct support for this hypothesis, BCA2-specific siRNA was utilized to
inhibit the expression of BCA2 in MDA MB 231 cells, followed by measurement of subsequent
levels of endogenous pAMPKThr172.

Suppression of BCA2 occurred in a siRNA

concentration-dependent manner (reaching 80% inhibition; Figure 9A); importantly, this was
accompanied by an 11-fold increase in phosphorylated AMPK. Total AMPK protein levels,
however, remained relatively unchanged (Figure 9A). To further confirm that the increase of
pAMPK was active, the phosphorylation status of acetyl-CoA carboxylase (ACC), a direct
downstream target of AMPK was assessed (Davies et al., 1990). Knock down of BCA2 protein
resulted in a concentration-dependent increase (up to 7-fold) in levels of p-ACC (S79), mirroring
pAMPK, while levels of total ACC were unchanged compared to the control (Figure 9A). The
non-silencing scrambled siRNA negative control had no effect on either BCA2 protein
expression or AMPK signaling (Figure 9A, lanes 2 vs. 1). When this experiment was repeated in
two other breast cancer cell lines, MCF7 and MDA MB 468 (Figure 9B and C), inhibition (68%
and 42%, respectively) of BCA2 expression by its siRNA again resulted in increased levels of
pAMPK1 (2.5- and 1.4-fold, respectively; Figure 9 B-C).
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A. Immunoblot of MDA MB 231 cells (grown in a 6-well plate 2ml/well) transfected with BCA2
siRNA (x-axis, µg) for 72 hrs (3µg = 0.1µM, 5µg = 0.2µM and 7µg = 0.27µM). Scrambled, nonsilencing siRNA, and untreated cells were used as controls. Cell extracts were used for Western blots
with specific antibodies as those in Fig.8 as well as pACC (Ser 79) and total ACC. Densitometry
analysis is representative of mean ± SEM for three independent experiments. p-AMPK was
normalized to total AMPKα, pACC to total ACC and BCA2 to β-Actin. Fold change was calculated
compared to the control. B, C. MCF7 (B) and MDA MB 468 cells (C) were transfected with 5 µg of
either BCA2 siRNA or scrambled control for assessment of the effect on pAMPK as done in part A.
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More evidence of BCA2 as an endogenous AMPK inhibitor is shown in Figure 10, where
the BCA2 gene was subcloned into a pCMV-tag2B vector construct and herein utilized to cotransfect HEK293T cells together with a pCMV6-XL5 AMPK α1-subunit containing construct.
HEK293T cells express low basal levels of AMPK and BCA2 (Figure 10, lane 1), making
them a good model for co-transfection experiments. Co-transfection of the AMPKα1 subunit and
the pCMV empty vector increased cellular levels of pAMPK (Figure 10, lanes 2 vs. 1), while
co-transfection of AMPKα1 and BCA2 had little or no increase in the basal level of pAMPK
(Figure 10, lanes 3 vs. 2 vs. 1), confirming that BCA2 inhibits basal levels of AMPK
activation. To determine whether BCA2 could also inhibit induced AMPK activation, the cotransfected cells were treated with AMPK activators metformin or AICAR. Metformin is an
indirect activator of AMPK, while AICAR is an analog of AMP and can therefore mimic its
cellular effect and directly bind its β regulatory subunit, activating AMPK in culture (Corton et
al., 1995).

A robust induction of pAMPK was observed in cells co-transfected with

AMPKand pCMV empty vector after treatment with metformin or AICAR (Figure 10, lanes 4
and 6 vs. 2). Importantly, this induction was almost completely inhibited by transfected BCA2
(Figure 10, lanes 5 vs. 4, and 7 vs. 6). Again, BCA2 transfection had little inhibitory effect on
total AMPK (Figure 10). Therefore, these transfection studies reveal that BCA2 is an inhibitor
of both basal and induced AMPK phosphorylation/activation. Also observed in response to
AMPK activators, was an increase in BCA2 levels (Figure 10, lanes 4 and 6 vs. 2), suggesting
that AMPK signaling may trigger BCA2 up-regulation as a feedback mechanism (see Figure 1420).
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Figure 10. BCA2 inhibits AMPKα1 phosphorylation and activation
Immunoblot of HEK293T cells co-transfected with BCA2 wt and AMPKα1 (2.5 µg each). After a
48 hr transfection, cells were either treated with metformin (20 mM) or AICAR (1 mM) for 6 hr,
or left untreated. Cell extracts were used for Western blots with specific antibodies as previously
stated. FLAG was used as a measure of transfection efficiency.
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Requirement of the BCA2 RING domain and S132/S133 phosphorylation sites for
inhibition of AMPK activation
To gain insight into the molecular basis by which BCA2 suppresses AMPK activation,
the requirement of its RING domain and S132/S133 phosphorylation sites, residues within its
predicted Akt-binding domain, were analyzed. The RING domain of BCA2 is critical for its E3
ligase function and a cysteine mutation to alanine, at positions 228 and 231, renders the protein
“ligase dead” and therefore ubiquitination negative (Burger et al., 2005), while AKT-mediated
phosphorylation of BCA2 has been reported to increase its stability (Amemiya et al., 2008;
Bacopulos et al., 2012). The serine 132 and 133 residues mutated to alanine would therefore
increase its ubiquitination/ autoubiquitination ability and subsequent degradation by the
proteasome. It should be noted that these serines were predicted to be phosphorylated by Akt, but
may be susceptible to phosphorylation by other kinases in addition to Akt, which needs to be
further characterized.
HEK293T cells were first co-transfected with the AMPKα1 subunit and wild-type (wt) or
a mutant (mt) variant of BCA2, followed by examination of the effect on basal p-AMPK1
levels by Western blotting. Again, an increase in basal pAMPK1 levels was seen when
AMPKα1 was co-transfected with the pCMV empty vector control, which was inhibited in the
presence of BCA2 wt (Figure 11A, lanes 1-3).
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Figure 11. The requirement of the BCA2 RING domain and AKT phosphorylation
sites for inhibition of AMPK (HEK293T cells)
A. Immunoblot of HEK293T cells (grown in 100 mm dishes) co-transfected with
AMPKα1 and BCA2 wt, RING mt or S132/S133 mt for the assessment of basal pAMPK
levels. B. Immunoblot of HEK293T cells co-transfected with a constant amount of
AMPKα1 (1 µg) and increasing amounts of BCA2 wt or mt (1 or 5 µg) treated with
metformin (20 mM) for 6 hr.
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However, co-transfection of the BCA2 RING mt failed to inhibit an increase in pAMPK1
(Figure 11A, lanes 4 vs. 3 and 2), indicating that the RING domain, and therefore the E3 ligase
function of BCA2, is required for negative regulation of AMPK activation. The co-transfection
of BCA2 S132/S133 mt still retained a partial inhibitory effect on pAMPK1 levels in this
experiment, compared to BCA2 wt and RING mt transfected cells (Figure 11A, lane 5 vs. 1-4),
suggesting that this mutant still confers enough stability (as shown by the level of FLAG) and
therefore has a partial inhibitory activity, perhaps due to its RING domain still being intact.
Levels of FLAG and total AMPKα proteins were used as a measure of transfection efficiency
and that of β-Actin as the loading control (Figure 11A).
To further assess the requirement of the BCA2 RING domain and predicted AKT
phosphorylation site, co-transfected HEK293T cells were treated with metformin (Figure 11B).
While transfection of BCA2 wt (1 and 5 µg) inhibited the induction of pAMPK1 by metformin
(Figure 11B, lanes 2 and 5 vs. 1), the BCA2 RING mt failed to do so (Figure 11B, lanes 4 and 7);
in fact, a large increase in pAMPK1 was seen in cells transfected with 5 g of RING mt BCA2
(lanes 7 vs. 4 and 1), confirming that the RING domain of BCA2 is critical for its ability to
inhibit both basal and inducible levels of pAMPK1, suggesting that the RING mt acts as a
dominant negative inhibitor of endogenous BCA2 function. However, the transfection of BCA2
S132/S133 mt also inhibited AMPK phosphorylation in a dose-dependent manner (Figure
11B, lanes 3 and 6 vs. 1) and this inhibition was even greater than that seen by BCA2 wt (Figure
11B lanes 3 vs. 2 and 6 vs. 5) in this experiment. As the serines predicted to be phosphorylated
by Akt within this domain of BCA2, the results with this site mt were not entirely expected.
While they may in part be explained by the intact RING domain of this construct, as seen under

53

basal conditions in Figure 11A, the molecular mechanism for such a large inhibitory effect this
mutant produces on inducible AMPK remains unclear and will be further investigated in the near
future.
Confirming these results in human breast cancer cells was done using MDA MB 231
cells transfected with increasing concentrations (1-5 µg/well) of wt BCA2 to observe the effect
on basal pAMPK1 levels. In Figure 12A, it can be seen that with increasing amounts of
transfected BCA2 wt, basal AMPK phosphorylation is prevented, with some slight activation
seen in the 1 µg lane (lane 3), but subsequent decrease with 3 and 5 µg of BCA2 wt (Figure 12A,
lanes 4 and 5 versus 3). The same experiment was repeated in MDA MB 231 cells transfected
with 1 and 3 µg of BCA2 wt, RING mt, S132/S133 mt or pCMV empty vector control, followed
by treatment of AICAR and measurement of the effect on induced pAMPK1 (Figure 12B).
The transfection of BCA2 wt had little inhibitory activity on inducible pAMPK levels (probably
due to already high basal levels of endogenous BCA2 and AMPK proteins; Figure 12B, lanes 2
vs. 1), while the transfected S132/S133 mt was again able to partly inhibit the induction of
AMPK activation (Figure 12B, lanes 3, 5 vs. 1). Interestingly, also observed was the decrease in
endogenous BCA2 protein in the presence of transfected S132/S133 mt compared to the RING
mt (lanes 3 and 5 vs. 4 and 6). This may be explained by the still robust ubiquitination ability of
this mutant (Amemiya et al., 2008) and therefore targeted degradation of endogenous BCA2.
Importantly, the BCA2 RING mt not only fully abolished the BCA2 inhibitory effect, but also
enhanced AICAR-mediated AMPK activation in a dose-dependent manner (Figure 12B, lanes 4,
6 vs. 1, 2). Taken together, our data demonstrate that BCA2 E3 ligase activity is essential for its
inhibitory function on both basal and inducible AMPK activation.
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Figure. 12 The requirement of the BCA2 RING domain and AKT
phosphorylation sites for inhibition of AMPK (MDA MB 231 cells)
A. Immunoblot of MDA MB 231 cells transfected with 1, 3 and 5µg of BCA2-FLAG
wt to observe the effect on pAMPK. B. MDA MB 231 breast cancer cells cotransfected with increasing concentrations of BCA2 wt and mt (1 or 3 µg), to detect
changes in inducible (by AICAR) pAMPK levels. The prepared cell extracts in each
experiment were used for Western blots with the specific antibodies as indicated.
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Requirement of PI3/AKT kinase signaling for BCA2-mediated AMPK inhibition
To determine the role of AKT signaling on BCA2-mediated AMPK suppression, the
chemical inhibitor of the PI3/AKT kinase signaling pathway, LY294002, was used. Treatment of
MDA MB 231 cells with LY294002 caused a dose-dependent inhibition (> 90%) of pAkt at
S473 associated with decrease levels of BCA2 protein (about 60%, Fig. 13A). Importantly, this
was also accompanied by a concentration-dependent increase in pAMPK1 levels (up to 4-fold;
Figure 13A, lanes 2-5 vs. 1). Moreover, in a kinetics experiment, 3-6 hr inhibition of pAkt (up to
90%) in MDA MB 231 cells occurred and was associated with BCA2 decrease (>75%), and an
up to 2-fold increase in pAMPK levels, which reached its highest point (almost 4.5 fold) at 24
h (Figure 13B, lanes 2-5 vs. 1). However, again there was an increase in BCA2 levels following
AMPK activation and return of pAkt at 6-24 h (Figure 13B), consistent with the idea that a
potential feedback pathway is present (see Figure 14-20). These data demonstrate that the doseand time-dependent inhibition of AKT activity leads to a decrease in BCA2 levels and
subsequently, significantly increased levels of AMPK activation.
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A

B

Figure 13. AKT inhibition decreases endogenous BCA2 protein levels, followed by increased
AMPK activation.
MDA MB 231 cells were treated with LY294002 in either a dosing study (A, 12 hr time point) or
a kinetics experiment (B, 10 µM). The included figures are representative of experiments done in
triplicate and the included densitometry is mean ±SEM of phosphorylated proteins (normalized to
total) and BCA2 to β-actin, compared to vehicle control (set to 1) for fold change expression. The
prepared cell extracts in each experiment were used for Western blots with specific antibodies to
pAKT (S473), BCA2, pAMPKa (Thr172), total AMPKa1, and β-actin as a loading control. LY =
LY294002
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Treatment of breast cancer cells with an AMPK activator increases endogenous BCA2
protein levels
In the previous experiments (Figures 10-13), an increase in endogenous levels of BCA2
in response to the activation of AMPK was noted. To test if AMPK signaling can in turn lead to
up-regulation of the BCA2 protein, MDA MB 231 cells were treated with various concentrations
of the direct AMPK activator, AICAR, for 2, 4 or 8 h, followed by measurement of the effect on
BCA2 by Western blotting (Figure 14). A clear dose- and time-dependent increase in BCA2
protein levels was observed, which corresponded to the induction of AMPK activation, as
measured by specific phosphorylation of pAMPK and pACC (Figure 14), demonstrating that
BCA2 increase is a consequence of AMPK activation. Since AKT can phosphorylate and
stabilize BCA2 (Amemiya et al., 2008; Bacopulos et al., 2012), we determined whether AICAR
treatment could also activate AKT. Indeed, levels of pAkt were increased in MDA MB 231 cells
in an AICAR concentration- and time-dependent fashion, correlating well with that of the
observed BCA2 protein increase (Figure 14).
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Figure 14. Activation of AMPK by AICAR increases BCA2 protein levels in
MDA MB 231 breast cancer cells.
Immunoblot of MDA MB 231 cells treated with AICAR at the indicated
concentrations and time points.

59

When MDA MB 231 cells were treated with metformin in a kinetics experiment, a timedependent increase in BCA2 protein levels were again observed, in association with an induction
of AMPK activation (Figure 15A). Furthermore, kinetics experiments utilizing MCF7 cells
treated with metformin (Figure 15B) or MDA MB 468 cells treated with AICAR (Figure 15C),
also produced increased levels of BCA2 and pAkt proteins, associated with AMPK activation.
Finally, the use of the chemical AMPK inhibitor, Compound C, not only suppressed activation of
AMPK1, but also inhibited the metformin-induced increase in BCA2 and pAkt in MDA MB
231 cells (Figure 16), suggesting the involvement of AMPK activity in a potential regulatory
feedback mechanism with pAkt and BCA2 (see Figure 20).
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Figure. 15 Activation of AMPK, by metformin or AICAR, increases BCA2 protein levels in
multiple breast cancer cell lines.
A. Immunoblot of MDA MB 231 cells treated for up to 12 hr with 20 mM metformin. B.
Immunoblot of MCF7, and C. of MDA MB 468 cells treated with 20 mM of metformin for up to 24
hours.
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Figure 16. Metformin mediated increase in BCA2 does not occur in the
presence of the AMPK inhibitor, Compound C.
MDA MB 231 cells were pre-treated with 20 µM of Compound C for 12 h (lanes 45) or untreated (lanes 2-3), followed by treatment with 20 mM metformin for 4 or 8
h. The prepared cell extracts in each experiment (representative of three repeats)
were then used for Western blots with specific antibodies as indicated.

62

To determine whether the metformin-mediated increase in BCA2 occurred on the
transcriptional level, BCA2 mRNA levels and promoter activity were assessed in both cotransfected HEK293T and MDA MB 231 cells before and after metformin or AICAR treatment
(Figure 17). From these experiments we were able to conclude that AMPK activation increases
levels of BCA2 protein only, but not mRNA. We also determined that BCA2 does not bind the α
subunit of AMPK directly (Figure 17).
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Figure 17. BCA2 mRNA or promoter activity do not increase in response to metformin or
AICAR and BCA2 does not inhibit AMPK by binding the α subunit directly
A. B. HEK293T or MDA MB 231 cells were co-transfected with a 1kb region of the BCA2
promoter and Renilla luciferase as a control, followed by treatment with metformin (20 mM, 6 hr)
or AICAR (1 mM, 6 hr). Optimal levels for luciferase expression were defined by initially
transfecting different ratios of BCA2 to Renilla and 1:100 was used. Data are normalized to Renilla
and expressed as Relative Luciferase Units (RLU) of BCA2/control. Means and standard error of 3
experiments done in triplicates are shown, of which no significant change in promoter activity was
observed in response to either treatment in either cell line. C. Quantitative PCR indicating no
significant fold change in BCA2 using MDA MB 231 breast cancer cells. Data are normalized to β
actin internal control. Graph depicts the mean and error bars of 2 experiments done in triplicates.
D. HEK293T cells were co-transfected with equal amounts (2.5 µg) of AMPKα and FLAG-tagged
BCA2 and immunoprecipitation was performed using 700 µg of protein and FLAG antibody. All
AMPKα was found to be in the unbound protein portion.
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Inhibition of BCA2 significantly enhances the ability of metformin to inhibit breast cancer
cell growth
If BCA2 is an endogenous inhibitor of AMPK phosphorylation/activation, it is logical to
assess the growth inhibitory potential of metformin in combination with BCA2 inhibition. To do
so, breast cancer MDA MB 231 (Figure 18A), MDA MB 486 (Figure 18B) and Hs578t (Figure
18C) cells were pretreated with BCA2 siRNA or negative control scrambled siRNA for 72 h,
followed by treatment with metformin at concentrations ranging from 1-30 mM for an additional
24 h. Cell growth status was then analyzed by MTT assay. Again, BCA2 siRNA, but not control
siRNA, inhibited the growth of MDA MB 231 breast cancer cells (59.2 vs. 2.5%; Figure 18A).
The combination of metformin and the control scrambled siRNA resulted in metformin dosedependent growth inhibition, 5.5, 31.0 and 41.2% for 5, 15 and 30 mM respectively (Figure 18A,
bars 3-5). Importantly, the addition of metformin to BCA2 siRNA-transfected cells resulted in
an even more significant reduction in growth, compared to metformin plus scrambled siRNA,
reaching 82.8% (p < 0.001) at 5 mM, 86.0% (p < 0.001) at 15 mM and 92.6% (p < 0.001) at 30
mM (Figure 18A, bars 7-9). MDA MB 468 and Hs578t cells (Figure 18B and C) showed also
favorable and statistically significant results when combining BCA2 siRNA with metformin,
compared to metformin alone. BCA2 siRNA alone was capable of inhibiting cell growth by
68.4% in MDA MB 468, followed by up to 89.7% inhibition with the addition of metformin (p <
0.001) (Figure 18B). Hs578t, while not as sensitive to such treatment (31.1% inhibition with
BCA2 siRNA), also reached up to 79% growth inhibition with the addition of metformin (p <
0.05) (Figure 18C).
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Figure 18. Inhibition of BCA2 enhances the anti-proliferative effect of metformin.
A. MTT assay using MDA MB 231 cells transfected with BCA2 siRNA (0.75 µg in a well of a 96well plate = 0.5µM) for 72 hr followed by metformin treatment at of 5, 15 and 30 mM for 24 hr.
Scrambled, non-silencing siRNA (0.75 µg) and untreated MDA MB 231 cells were used as
controls. Included figure is representative of three repeats and the data are mean ± SEM of those
and based on an average of 6 observations for each condition in each experiment (two-tailed t test
with Welch’s correction comparing the means of combination treatment to metformin alone). B, C.
MDA MB 468 (B) and Hs578t cells (C) were used for reproducibility of those results shown in
part A and are as previously described for the indicated concentrations of metformin.
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Similarly, a soft agar, anchorage-independent, colony formation assay was performed to
further confirm the efficacy of metformin plus BCA2 inhibition using breast cancer MDA MB
231 cells, which were treated with either metformin alone, the PI3 Kinase/AKT inhibitor
LY294002 alone (which leads to BCA2 destabilization), or their combination (Figure 19). The
results show that the metformin and LY294002 combination is more effective than either agent
alone, reaching 57.9 and 74.3% inhibition vs. 22.5 and 40.2% with 10 and 20 mM metformin
alone vs. 14.8% with 10 M LY294002 alone (bars 5, 6 vs. 2-4, p < 0.001; Figure 19). Although
Akt has been implicated in a number of cancer cell survival pathways and is therefore not
specific to BCA2, previous published works, together with our positively correlated data herein,
indicate it to be important for BCA2 stability. This experiment, furthermore, suggests that the
disruption of the BCA2-mediated feedback regulatory loop may be a new avenue for improving
metformin efficacy in breast cancer patients with aggressive breast tumors that overexpress
BCA2.
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Figure 19. AMPK activation and Akt inhibition supresses MDA MB 231 colony
formation
Soft agar colony formation assay using MDA MB 231 cells. Metformin (M) and LY294002
(LY) were added at concentrations shown for 6 days. Images (inserted) shown are a
representative of 6 independent wells from the same treatment. Bar graph is representative of
repeated experiments and the data are mean ± SEM based on an average of 6 wells per
condition per experiment (two-tailed t test with Welch’s correction comparing means of the
combination treatment to metformin alone) ***p<0.001.
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Discussion
In conclusion, BCA2 is an endogenous inhibitor of AMPK activation and the inhibition
of BCA2 therefore increases the efficacy of metformin (Figure 20). Investigated was if, and
how, BCA2 regulates the tumor suppressing AMPK signaling pathway. Toward this goal, BCA2
was identified as an inhibitor of an upstream event controlling AMPK activation (Figure 20 and
see following discussion). Furthermore, the data presented suggest the existence of a potential
feedback mechanism, whereby AMPK activation increases BCA2 protein expression (Figure
20). Although the existence of such a phenomenon adds to the controversy surrounding the use
of the AMPK activator metformin for the treatment of breast cancer, it provides newfound
awareness for the limitations that this type of therapy may have.
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Figure 20. Proposed schematic for BCA2/AMPK feedback mechanism
At the basal level, AKT works to stabilize BCA2 so that it is free to ubiquitinate protein
substrates, including those controlling phosphorylation/ dephosphorylation of AMPKα1 at Thr
172, targeting them for degradation via ubiquitin-proteasome pathway, resulting in inhibition of
AMPK signaling in breast cancer cells. The activation of AMPK by metformin or AICAR,
however, increases BCA2 protein levels, inciting cancer cell survival involving PI3K/Akt.
Therefore, the balance of AMPK and PI3K/AKT/BCA2 might control breast cancer cell
sensitivity to metformin therapy and the tumor cell life-death switch.
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Immunoprecipitation experiments have revealed that BCA2 does not bind the AMPK α1
subunit directly (Figure 17), leading to the proposition that its negative effect is a result of BCA2
E3 ligase-mediated degradation of a target protein that is located upstream of AMPK and is
responsible for regulating the (de)phosphorylation of the α1 subunit (Figure 20). On this account,
and in conjunction with Wayne State University’s Proteomics Core, titanium dioxide (TiO2)
phosphopeptide enrichment using MDA MB 231 cells treated with BCA2 specific siRNA or
control siRNA, followed by mass spectrometry was performed to identify potential leads that
would have a place in the regulatory mechanism outlined herein. The preliminary results of this
work are discussed in the next chapter. Furthermore, data in Figures 11 and 12 also suggest that
the BCA2 target protein is a substrate of its E3 ligase activity since the RING domain is required
for its inhibitory effect. Consistent with this argument, if this were a direct effect on the α1
subunit, one would expect the RING mt to have a similar effect to the wt, as this would be the
substrate-binding ubiquitination site. Also supportive in this regard is that no change in total
AMPKα was observed (Figures 11-12).
Phosphorylation is possibly the most common occurring post-translational protein
modification, often resulting in changes in protein conformation and stability, and BCA2 is no
different in this regard. The fact that the transfected BCA2 S132/S133 mt also produced an
inhibitory effect on basal pAMPKα1 in HEK293T cells (Figure 11A) points to the primary
importance of an intact RING domain for its inhibitory activity. Furthermore, the even greater
inhibitory effect of this mutant protein seen in the presence of metformin/AICAR (Figure 11B
and 12B) also suggests the need for a more detailed characterization of these serine mutations
made within the predicted Akt phosphorylation site. It is possible that other kinases may be in
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competition for phosphorylation of BCA2 at these sites and delineating the function of each
residue under such conditions that induce AMPK activation, as in Figure 11B and 12B, will be
determined in future work. Also observed was that the level of endogenous BCA2 in breast
cancer cells transfected with S132/S133 mt after AICAR treatment was lower than that with
BCA2 wt and RING mt (Figure 12B). This could also be due to the ubiquitination ability of this
mutant (Amemiya et al., 2008), which would target the endogenous BCA2 protein for
degradation. The detailed mechanisms behind this phenomenon need to be investigated.
Therefore, the BCA2 mutant variant analysis data draws at least one main conclusion: an
event upstream of AMPK, regulating its (de)phosphorylation and activation, is likely the
substrate of BCA2 E3 ligase activity (Figures 11A and 20).

The importance of AKT in

suppressing AMPK activation via BCA2 was confirmed in Figure 13 where the use of a
PI3/AKT kinase inhibitor produced a correlative effect between pAkt inhibition, BCA2 protein
decrease and AMPK activation. These data suggest that BCA2-mediated inhibition of AMPK
activation on the basal level is AKT-dependent.
Moreover, these data show that the use of metformin and AICAR not only activates
AMPK signaling, but also produces a subsequent increase in BCA2 protein levels (Figures 1415). This increase in BCA2 was further shown to be specific to AMPK activation, as it does not
occur in the presence of the AMPK inhibitor, Compound C (Figure 16). Given what is already
known about BCA2 and its dependence on such a classic growth promoting signal as AKT, it is
logical to suggest that the observed BCA2 increase in response to AMPK activation by
metformin or AICAR is related to a potential cell survival mechanism, a to-be-determined
feedback loop ignited by AKT, and may incite cancer cell growth (Figure 20). This argument
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was supported by increased levels of pAKT and BCA2 proteins in AICAR- or metformin-treated
breast cancer cells (Figures 14-15). Directly opposing these results are those of Zakikhani et al,
who reported inhibition of pAkt levels in response to metformin (Zakikhani et al., 2010).
However, it is important to note that the difference in experimental conditions between
Zakikhani et al’s work and the current study may affect what results are observed. For instance,
Zakikhani et al performed metformin treatment under serum-starved conditions for 72 hours,
whereas the experiments done herein utilize complete media containing 10% serum. In addition,
for the purpose of these molecular studies, AMPK activation at shorter time points is sufficient to
observe the increase in pAkt and BCA2. Furthermore, literature in support of AMPK activating–
pAkt results can be seen in various cancer types (Kuznetsov et al., 2011; Leclerc et al., 2010;
Sengupta et al., 2007; Tao et al., 2010). The reason for these discrepancies is still unclear,
however, published reports in agreement with both observations, are in existence.

To confirm

the regulatory role of BCA2 on AMPK activation, three breast cancer cell lines were treated with
metformin in the absence or presence of BCA2 inhibition. Shown is that through the inhibition
of BCA2, either directly by siRNA, or indirectly by PI3/AKT kinase inhibition, the desirable
anti-cancer effect of metformin is significantly enhanced (Figures 18-19).
While some preliminary clinical data are available that test metformin’s anti-tumor effect
in breast cancer patients, it is yet to be proven that metformin improves the overall current
clinical outcome for breast cancer victims. In the laboratory setting, the mechanisms underlying
its reported preclinical anti-cancer activity are still unclear (Campagnoli et al., 2012; Decensi et
al., 2010; Evans et al., 2005; Goodwin et al., 2008; Hadad et al., 2011). Most of the best
available therapies are beneficial to specific tumor types, for example, anti-estrogens for
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hormone responsive breast cancers (1998; Jordan, 2003) or herceptin for Her2 positive cases
(Dent et al., 2013).

Taking into account the mixed reports in the literature on the effects of

AMPK activation in a cancer context, it is important to consider that metformin use may also
have beneficial or adverse effects depending on the cancer type and background, including the
overexpression of BCA2. Therefore these data convey that the screening of breast tumors,
particularly those with a more aggressive phenotype, for BCA2 may not only provide a strong
predictor of which patients may respond to metformin-based therapies, but also suggest that the
combination of metformin and a BCA2 inhibitor may be a more effective anti-cancer strategy
than metformin alone in which the desirable reprogrammed cellular energy homeostatic state,
characteristic of AMPK activation, could be maintained.

74

CHAPTER 4
RESULTS
Preliminary search for candidate BCA2 substrate proteins controlling AMPK activation
and BCA2 small molecule inhibitors

The search for BCA2 protein substrates controlling AMPK (de)phosphorylation and
activation
As a newly identified negative regulator of AMPK activity in breast cancer cells, solving
for the missing factor, on which BCA2 exerts its inhibitory function, is an important aspect in the
complete characterization of the governing mechanism outlined within the last chapter. As an
E3 ligase, one would expect its inhibitory function to be carried out by way of ubiquitination
(and therefore degradation by 26S proteasome) of some upstream event controlling
(de)phosphorylation of AMPK. Since BCA2 does not bind to the α subunit directly (Figure 17),
identifying this highly sought after piece of information required the assistance of Wayne State
University’s proteomics core and a large-scale mass spectrometry (MS) experiment. MDA MB
231 breast cancer cells were treated with either BCA2 specific siRNA or control siRNA in three
independent experiments and a small aliquot of each preparation was used in Western blots to
verify the BCA2 knock down (Figure 21) and the remaining samples were sent out for titanium
dioxide (TiO2) phosphopeptide enrichment and MS analysis.
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91.2%

33.6%

93.9%

Figure 21. Verification of BCA2 knockdown prior to TiO2 enrichment and
mass spectrometry
The confirmation of three individual siRNA experiments is shown. Small
aliquots of each experiment were validated by western blotting (30µg). Dry
pellet samples of each result shown in this figure were sent to the proteomics
core for further analysis.
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In preparing for this study, the hypothesis was that an AMPK upstream kinase was the target of
BCA2 E3 activity and because many phosphorylated proteins are present in low amounts,
enrichment before and after the knockdown of BCA2 (and before MS anaylsis) by TiO2 beads
was required. Protein identification was determined by using the X! Tandem software, which
matched identified mass spectra with peptide sequences in the SwissProt_2013_04 database
selected for Homo sapiens (see materials and methods section). Identified peptides that were
present at greater than 80.0% probability, as per the Peptide Prophet algorithm, were
acknowledged (Keller et al., 2002) and protein probabilities assigned by the Protein Prophet
algorithm (Nesvizhskii et al., 2003) (see Materials and Methods). All results and statistical
analysis discussed within are preliminary and were displayed and organized in Scaffold
Proteome Software. Of particular interest were those phosphorylated proteins detected to be
comparatively increased following the knockdown of BCA2 to control siRNA. At a threshold of
80%, 692 total proteins were identified in this study, which included a mixture of those that
increased or decreased following knockdown of BCA2. Of these, 36 were specific to BCA2
siRNA inhibition, 160 to the control and 496 overlapped and remained relatively unchanged
(Figure 22).
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Figure 22. Van Diagram Summary of Mass spectrometry results
The total of 692 protein identified can be broken down as depicted here.
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Statistically significant changes were found in seven different phospho-proteins, and although
these changes refer to a decrease in their level after BCA2 knockdown, their identities are
presented in Table 1. Those phospho-proteins found to be increasingly present after treatment
with BCA2 siRNA are recorded in Table 2. Furthermore, any other phospho-proteins found to
subsequently be changed in phosphorylation status are listed in Table 3 and all happen to be
decreased.

Many of the proteins turned out to have overlapping roles in cytoskeletal

organization, filament crosslinking, mRNA processing, transcription, chromatin remodeling and
organization. However, when analyzing the data in terms of which phospho-proteins may best
fit the hypothesized regulatory mechanism discussed in Chapter 3, only two may be suitable.
Serine/threonine-protein phosphatase 2A regulatory subunit delta isoform (2A5D or PP2A) and
Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) may function in the upstream (in)activation
of AMPK and should therefore be considered as potential ubiquitination targets of BCA2.
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Table 1. Statistically significant proteins following BCA2 knockdown (all down-regulated)
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Table 2. Phospho-proteins upregulated following BCA2 knockdown
Phospho-protein of interest is marked in red.
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Table 3. Other proteins found to be down regulated following BCA2 knockdown
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Table 3. Continued Other proteins found to be down regulated following BCA2 knockdown
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Table 3. Continued Other proteins found to be down regulated following BCA2 knockdown
Proteins of interest are marked in red.

84

Table 3. Continued Other proteins found to be down regulated following BCA2 knockdown
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PP2A has been reported to inhibit the activation of AMPK and is therefore overactive in some
cancer types (Park et al., 2013; Seshacharyulu et al., 2013).

Because the number of

phosphopeptides associated with its expression was found to decrease following BCA2
knockdown in our MS screen, if BCA2 plays a role in keeping PP2A active on a basal level in
breast cancer cells, it may be indirect; perhaps by directly targeting an inhibitory kinase of PP2A
and thereby inhibiting AMPK. Furthermore, while this may be one of the ways in which cancer
cells regulate the anti-tumor activity of AMPK, the effect of this particular PP2A regulatory
subunit delta isoform on AMPK activity, and especially its relationship to BCA2, remains to be
determined.
AMPK activation by CaMKK occurs in an AMP independent manner and is triggered by
a rise in Ca2+ concentration (Hawley et al., 2005; Woods et al., 2005). One such way in which
cellular Ca2+ concentration may rise is as a consequence of the binding of inositol triphosphate to
ITPR3, which in turn initiates the activation of this receptor’s second messenger Ca2+ release
function. Therefore, it is tempting to postulate that BCA2 may inhibit AMPK activation in
breast cancer cells by ubiquitination and degradation of ITPR3, which would prevent Ca2+
mediated activation of AMPK by CaMKK.

Yet others have shown Ca2+ to mediate the

activation of PP2A, and therefore inhibition of AMPK, suggesting a two-fold function of
intracellular Ca2+ on AMPK activity (Davare et al., 2000; Janssens et al., 2003). As a receptor
tyrosine kinase, degradation would occur by way of the lysosome and the endocytic pathway.
Indeed, BCA2 has previously been indirectly implicated in the endocytosis of another tyrosine
kinase receptor, EGFR (Miyakawa et al., 2009). Whether or not ITPR3 is a substrate of BCA2
activity remains to be determined and the status of PP2A and CaMKK need to be better defined
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in regards to the BCA2 mediated inhibitory effect of AMPK.

Importantly though, the

preliminary results of this proteomics experiment have certainly paved the way for doing so.
Furthermore, it would be interesting to assess the position of CaMKK in the positive feedback
mechanism reported in response to metformin treatment of breast cancer cells. Considering the
mixed reports on CaMKK facilitated activation of AMPK promoting or inhibiting tumor cell
growth, clarifying its role in the current context is an important aspect for the further
development of AMPK as a molecular drug target.

The preliminary search for DSF analogs as potential BCA2 inhibitor
Previous work has suggested that DSF inhibits BCA2 autoubiquitination activity in an in
vitro assay using the recombinant protein (Brahemi et al., 2010; Kona et al., 2011). Because a
multitude of anti-tumor effects have been described for DSF, it cannot be considered a BCA2
inhibitor solely. On this account, several “zinc-affinic” DSF analogs were synthesized and
assessed for their ability to inhibit both breast cancer cell proliferation and BCA2
autoubiquitination in vitro (Brahemi et al., 2010). The screening of these compounds led to the
conclusion that some analogs were relatively more potent than others, with the DSF analog, D24,
and dithio(peroxo)thioate, DPT001, being most potent (IC50 in the sub-micromolar range).
Conversely, the structurally similar dithiocarbamates and benzisothiazolones (no disulfide bond)
were all inactive (Figure 23). These data are presented in Table 4 (Brahemi et al., 2010) .
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Figure 23. Analogs with BCA2 inhibiting potential by way of zinc-ejection
Series of compounds structurally related to DSF were synthesized so that SAR
relationships to BCA2 and cancer cell growth inhibition could be performed
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Table 4. DSF analog and carbamo(dithioperoxo)thioate activity in human breast cancer versus
normal cell lines
Novel lead compounds are marked in red.
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Subsequent SAR analysis found the N(C=S)S-S motif to be a common denominator for this
difference (see Figure 5).

Following this discovery, a group of 77 N(C=S)S-S containing

compounds (listed in Table 5) were received from the NCI for further testing in breast cancer
cells as potential BCA2 inhibitors. The evaluation of all 77 in MCF7 and MDA MB 231 cells
has produced 15 leads that are active in the micromolar range in both cell lines (IC50 less than or
around 1 µM) and are summarized in Table 6.

Whether they are capable of specifically

inhibiting BCA2 autoubiquitination, however, remains to be determined. Moreover, as the data
in Chapter 3 suggest, the combination of a BCA2 inhibitor plus metformin may be more
effective than metformin alone and therefore experiments testing the combination of these drugs
with metformin may prove to be a valuable direction for future translational in vivo work. Since
its reported discovery in 2005, much has been learned about the regulation of BCA2 and its
binding partners, but still the need for more information in regards to its downstream substrates
and a better understanding of why it is overexpressed in the diseased state exists. Only then can
the synthesis and screening of novel compounds be further developed for its specific inhibition.
Currently, a first generation of BCA2 inhibitors does exist and while the design of more specific
agents is needed, access to the additional NCI compounds outlined in this chapter is certainly a
good start.
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Table 5. NCI compounds containing the “disulfonyl-methanethione” group
Novel lead compounds are marked in red.
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NCI Drug Number

MCF7 IC50 ±SD (µM)

MDA MB 231 IC50 ± SD (µM)

1771 – H/7

0.06 ± 0.5

0.06 ± 0.007

16847 – T/2

0.03 ± 0.002

0.09 ± 0.005

49512 – Y/2

1 ± 0.03

1 ± 0.05

59637 – G/2

0.04 ± 0.3

0.05 ± 0.02

66933 – L/3

0.3 ± 0.07

0.3 ± 0.05

68090 – S/1

0.07 ± 0.2

0.3 ± 0.02

160617 – R/1

0.05 ± 0.1

0.09 ± 0.003

342008 – H/1

0.05 ± 0.01

0.4 ± 0.02

402538 – Y/6

0.3 ± 0.01

0.9 ± 0.003

403854 – G/2

0.05 ± 0.003

0.9 ± 0.05

62291 – V/2

0.05 ± 0.002

0.3 ± 0.01

645616 – P/1

0.2 ± 0.005

0.6 ± 0.02

645619 – S/1

0.04 ± 0.05

0.04 ± 0.003

298135 – S/1

0.2 ±0.01

0.5 ± 0.006

290661 – T/1

0.5 ± 0.02

0.6 ± 0.007

Table 6. Lead NCI compounds and their respective activity in breast cancer cells
MCF7 and MDA MB 231 cells were tested against each compound. All have IC50
concentrations in the micromolar range with a small difference (<10 fold) in potency between
the two breast cancer cell lines in select cases.
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CHAPTER 5
RESULTS
The need for novel molecular targets in the treatment of cancer goes without saying.
BCA2, although first isolated from an invasive breast cancer cell line, is also expressed in
prostate cancer cells and perhaps in many other cancer cell types making it a great candidate for
therapeutic intervention. In the current Chapter, data presented in Chapter 3 are expanded to
include prostate cancer cells, where a similar negative correlation of BCA2 and pAMPK in
human prostate cancer cells is described. In addition, using several human breast and prostate
cancer cell lines, a decrease in BCA2 protein levels during reduced serum conditions, (indicative
of G1 phase) and reappearance once the cells are synchronized with the re-addition of 10% FBS
(indicative of progression into S phase), inhibitable by cycloheximide, is described.

This

phenomenon also occurs at the BCA2 mRNA level. Furthermore, BCA2’s cytoplasmic
localization is more prominent in aggressive breast tumor cell lines, as opposed to the less
aggressive, estrogen receptor-positive, breast cancer cells.

BCA2 nuclear and cytoplasmic

expression levels were also found to be altered during the serum reduced conditions, as well as
under metformin or AICAR treatment conditions.

Results

BCA2 and pAMPK (Thr172) are inversely expressed in prostate cancer cells and
metformin treatment increases the expression of both proteins
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To investigate the potential relationship between BCA2 and AMPK activation, first we
assessed the basal expression of these proteins in a panel of four prostate cancer cell lines (Figure
24). An inverse relationship between BCA2 and pAMPK1 (Thr172) was observed: those cell
lines with higher levels of BCA2, like LNCaP and DU145, have lower pAMPK1 (Thr172)
levels when compared to the other two examined, namely C4-2B and PC3, which contain
relatively lower amounts of BCA2, but higher levels of pAMPK1 (Thr172) (Figure 24).
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0.65

0.26
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Figure 24. Relationship of BCA2 to pAMPK in prostate cancer cells
The assessment of basal BCA2 and pAMPK protein expression levels in the four
indicated human prostate cancer cell lines. Exponentially growing cells were lysed for
Western blotting analysis with specific antibodies to BCA2, pAMPK (Thr172), total
AMPKa1, and β-actin (loading control).
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Previous work (Buac et. al., 2013) has revealed an increase in BCA2 levels in breast
cancer cells after treatment with metformin. To determine if this also occurs in prostate cancer
cells, PC3 cells were treated with 20 mM metformin for up to 12 h (Figure 25A) and the effect
on pAMPK and BCA2 protein levels observed. AMPK activation occurred as early as 2 hours in
these cells, which remained high for the course of the time course experiment (Figure 25A).
BCA2 levels increased slightly at 2 h and further increased at 12 h (Figure 25A). A similar
result was seen when LNCaP cells were treated with metformin (data not shown). The use of the
chemical AMPK inhibitor, Compound C, in PC3 and LNCaP cells suppressed basal levels of
pAMPK1 and also showed some inhibition of basal level of BCA2 expression (Figure 25 B and
C). Therefore, prostate cancer cells exhibit an inverse correlation between BCA2 and pAMPK
protein levels and metformin treatment can increase levels of both, but compound C can inhibit
BCA2 protein levels in these cells.
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Figure 25. Metformin mediated activated of AMPK also increase BCA2 protein
levels, inhibitable by compound C
A. Immunoblot of PC3 cells treated with metformin (20 mM) at the indicated time
points. B-C. PC3 (B) and LNCap cells (C) treated with the AMPK inhibitor, compound
C (20 µM) for up to 20 h.
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BCA2 RNA and protein expression changes in response to serum reduction (G1/S phasedependent)
To determine whether BCA2 protein expression may be cell cycle-dependent, we reduced
the serum concentration of growth media for prostate and breast cancer cells that express high
levels of BCA2 from 10% to 1% FBS (G1 phase) for up to 72 or 96 hours and then observed the
effect on BCA2 protein expression by Western blotting (Figure 26). Panels in Fig. 26A and B
are of LNCaP and C4-2B prostate cancer cells and show a clear decrease in BCA2 protein
expression when these cells are in serum reduced conditions (G1 phase) (Figure 26A and B, lanes
4 and 5 vs. 1). After 24 hours of 10% FBS release (S phase), BCA2 protein expression returned
to a level similar to that of the exponentially growing control (Figure 26A and B, lane 6 vs. 1).
Furthermore, MDA MB 231 and MCF7 breast cancer cells produced similar results under these
conditions. Serum starvation in MDA MB 231 and MCF7 cells was performed for up to 96
hours (Figure 26C and D), since these cells were not as sensitive to serum withdrawal as the
prostate cell lines used. Once again, a decrease was observed in BCA2 protein levels during the
expected G1 phase in MDA MB 231 cells (Figure 26C, lanes 2-4 vs. 1), followed by an increase
of the protein once FBS is added once again (S phase) for a 24-48 hour release period (lanes 5
and 6). Figure 26D depicts the same effect in MCF7 cells. Cyclin A was used as an S phase
marker and β-actin or PARP was the loading control. Therefore these results suggest that BCA2
protein expression is low under reduced serum conditions and may indicate a correlation of
BCA2 expression and progression from the G1 to S phase of the cell cycle.
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1% FBS

1% FBS

10% FBS

10% FBS

2.20 1.97 1.72 1.23 0.52 2.47

1% FBS

10% FBS

1.15 0.73 0.52 0.29 1.05

1.05

1% FBS

10% FBS

1.06 1.11 0.74 0.56 0.17 0.71 1.18

Figure 26. BCA2 protein is sensitive to G1/S phase arrest
LnCaP (A) and C4-2B (B) prostate cancer cells were serum starved for up to 72 hours,
indicating G1 phase, and reintroduction of 10% serum for up to 24 hrs is denoted as S phase.
Breast cancer MDA MB 231 (C) and MCF7 cells (D) were serum-starved for up to 96 hours
(G1) and then grown in 10% serum-containing medium for up to 48 hrs (S Phase), showing
similar sensitivity to that seen in prostate cancer cells. This was followed by Western blot
assay using specific antibodies to BCA2, Cyclin A (as an S phase marker) and β-Actin or
PARP (as a loading control).
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During the G1 phase of the cell cycle, DNA transcription is minimized and no further
production occurs until the cells progress successfully in S phase (Orlando et al., 2008). To
assess if BCA2 mRNA levels are also G1/S phase-related, breast cancer MDA MB 231 cells
were serum starved, followed by addition of complete medium containing 10% FBS, as in Figure
27C. RNA was then extracted for PCR amplification and the cDNA prepared and analyzed.
Figure 27A depicts these results, where BCA2 mRNA levels can be seen to drop off after 72
hours when cells were in low serum-containing medium and to an even lower level after the 96
hour starvation (Figure 27A, lane 2, 3 versus 1), with -actin used as control, After serum was
added back into these cells for 24 or 48 h, BCA2 mRNA reappeared and reached level similar to
that of the exponentially grown cells (Figure 27A, lanes 4 and 5 vs. 1).
To further confirm that the increase in BCA2 protein seen during the re-addition of 10%
FBS (S phase) (Figure 26) was due to new protein synthesis, prostate cancer LNCaP (Figure
27B) and breast cancer MDA MB 231 cells (Figure 27C) were again serum starved, followed by
release into S phase by re-addition of serum in the growth medium for 24 or 48 h, with or
without the protein synthesis inhibitor cycloheximide. Again, BCA2 protein level was increased
when cells crossed were released from the low serum conditions and so the G1/S boundary
(Figure 27B-C, lanes 2, 3 vs. 1); however, such S phase-associated BCA2 protein increase was
completely blocked in the presence of cycloheximide (Figure 27B-C, lanes 4, 5 vs. 2, 3). These
results allow us to conclude that the subsequent BCA2 increase following release into S phase by
the addition of whole serum may be due to new BCA2 protein synthesis.
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10% FBS
1% FBS

10% FBS
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Figure 27. BCA2 transcription and protein synthesis at the G1/S phase
A. mRNA analysis of BCA2 (~198 b.p = base pairs) in MDA MB 231 cells serum starved
as in Figure 27. B-C. Immunoblot of prostate cancer LnCaP (B) and breast cancer MDA
MB 231 cells (C) at G1/S with or without cycloheximide. These cells were serum starved
for up to 48 hrs and then allowed to proceed into S phase for an additional 48 hours in 10%
FBS. Cycloheximide (CHX, 10 µM) was added for 24 or 48 hrs as indicated in the
corresponding lanes. β-actin was used as a loading control.
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BCA2 localizes to the nucleus and cytoplasm of a breast cancer cell
BCA2 was previously reported to be present in both the nucleus and cytoplasm (Burger et
al., 2005). To better characterize its cellular distribution, a panel of breast cancer cell lines was
selected and used for fractionation of the nucleus and cytoplasm, followed by assessment of
BCA2 localization (Figure 28A and B). Cell lines shown in Figure 28A are those typically
classified as triple negative, void of estrogen receptor (ER), progesterone receptor (PR) and
Her2, and therefore more aggressive than other breast cancer cells (Frank et al., 2013; Goncalves
et al., 2013). BCA2 expression in both the nucleus and cytoplasm was seen, with a higher level
in the cytoplasm (Figure 28A, lanes 2, 4, 6 vs. 1, 3, 5) amongst this group of triple negative
breast cancer cells. Figure 28B depicts the estrogen receptor-positive cell lines where we see a
similar distribution of BCA2 between the nucleus and cytoplasm throughout, although in varying
amounts specific to the cell line. For example, DCIS.com cells have more in each compartment
than the others (Figure 28B, lanes 3 and 4). Histone 3 (H3) and -tubulin were used as nuclear
and cytoplasmic markers, respectively.
The immunofluoresence data (Figure 28C) also further supports the fractionation results
shown in Figure 28A and B. In this experiment we again observe both nuclear and cytoplasmic
BCA2 expression in the three cell lines (MDA MB 231, T47D and MCF7) shown (Figure 28C).
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Figure 28. BCA2 nuclear and localization studies in breast cancer cells
A-B. Fractionation of nucleus from cytoplasm in a panel of breast cancer cell lines
divided as triple negative (A) and estrogen receptor-positive lines (B). β-Tubulin
was used as the cytoplasmic control and Histone 3 (H3) as the nuclear control. C.
Immunofluoresence data of BCA2 localization in MDA MB 231, MCF7 and
T47D breast cancer cells. Cells were counterstained with DAPI for nuclear signal
and rabbit-TRITC secondary used for BCA2.
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Changes in BCA2 protein localization at the G/S boundary and upon AMPK activation
BCA2 protein levels increase after release of serum starvation conditions and therefore
crossing of the G1/S border (Figures 26-27).

To study where this potentially cell cycle-

dependent changes in BCA2 protein reflects changes in distribution between the cytoplasm
versus nuclei, breast cancer MDA MB 231 cells were collected under the following conditions:
exponentially growing (asynchronized, lanes 1-2; Figure 29); serum starved for 96 h (lanes 3-4);
or released into S phase by adding 10% FBS for 24 or 48 h (lanes 5-8). Cells were then used for
fractionation of cytoplasm and nuclei. BCA2 levels were then determined in each fraction by
Western blotting. Compared to asynchronized cells, the nuclear but not cytoplasmic BCA2 level
in G1 cells, was greatly decreased (Figure 29, lanes 3, 4 vs. 1, 2). When G1 and S preparations
were compared, nuclear BCA2 increased after 24 h of release from G1, but decreased again at 48
h; however the cytoplasmic BCA2 protein level was increased at 24 h and remained high after 48
h of crossing the G1/S boundary (Figure 29, lanes 5-8 vs. 3, 4). The levels of pAMPK, but not
total AMPK were increased in both cytoplasmic and nuclear fractions after 48 h release from G 1
blockade (Figure 29, lanes 7-8 vs. 3-4). Interestingly, again an inverse relationship between
BCA2 and pAMPK in both cytosol and nuclei was seen. For example, in nuclear fractions of G1,
and 48 h after release preparations, a low level of BCA2 and relative high pAMPK were
observed while in the nuclear fraction of the 24 h release sample, high BCA2 and decreased
pAMPK were detected. These data suggest that both cytoplasmic and nuclear BCA2 protein
respond to cell cycle synchronization and progression.
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Figure 29. Changes in BCA2 localization during the cell cycle in MDA MB
231 breast cancer cells.
MDA MB 231 cells were G1/S phase arrested followed by fractionation and
analysis by Western blot. β-tubulin was used as the cytoplasmic control and
Histone 3 (H3) as the nuclear control.
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Recently reported was that AMPK activation (by either the anti-diabetic agent metformin
or the direct AMPK activator AICAR) increases BCA2 protein expression levels in human breast
cancer cells via a potential AKT-mediated feedback mechanism (Buac et. al., 2013). To study the
cellular localization of BCA2 protein induced by AMPK activation, MDA MB 231 cells were
treated with metformin for 4 or 8 h and then fractionated. The results (Figure 30A) show that the
increase in BCA2 protein by metformin treatment occurs in both the cytoplasm and nuclei,
compared to the control, at 4 and 8 hour time points (Figure 30A, lanes 3-6 vs. 1-2). Similarly,
when cytoplasmic and nuclear fractions were prepared from MDA MB 231 cells treated with
AICAR, an increase in cytoplasmic BCA2 was apparent, while nuclear BCA2 increased only at 8
hr time point (Figure 30B). The induction of pAMPK by metformin or AICAR occurred mainly
in the cytoplasm (Figure 30A-B). Our results support the idea that AMPK signal triggers an
increase in cytoplasmic and nuclear BCA2 protein that may play a role in the tumor cell survival.
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Figure 30. Changes in BCA2 localization as a result of AMPK activation in MDA MB 231
breast cancer cells
MDA MB 231 cells were either treated with Metformin (A) or AICAR (B), followed by
fractionation and Western blot. 20 mM metformin and 1 mM of AICAR were used for the
indicated time points. β-Tubulin was used as the cytoplasmic control and Histone 3 (H3) as the
nuclear control.
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Discussion
BCA2 was discovered almost a decade ago and research efforts to date have culminated
in numerous published works linking its expression to breast cancer development and
progression (Buac et al., 2013;(Amemiya et al., 2008; Bacopulos et al., 2012; Burger et al., 2006;
Burger et al., 2005; Burger et al., 2010; Kona et al., 2012) . However, others have also reported
an interesting protective role for BCA2/Rabring7 in HIV, where it functions to accelerate the
degradation process of viral particles tethered to the cell surface, thereby restricting HIV-1
release from infected cells that are tethrin dependent (Miyakawa et al., 2009). Another recent
article, by Aguilar-Hernandez et al., describes the evolutionary process and domain structure of
Rabring7/BCA2, largely conserved amongst eukaryotes, but shown in this work to expand to
angiosperms and even have ubiquitin binding ability (Aguilar-Hernandez et al., 2013). The
collection of such works leads to one comprehensive conclusion: continuing to extensively
characterize this protein will not only build upon our knowledge of RING-finger ubiquitin E3
ligases in general, but will also promote the synthesis and development of targeted agents for
BCA2 inhibition in those tumor types exhibiting its overexpression.
In this chapter, an inverse relationship between BCA2 and pAMPK in prostate cancer
cells (Figure 24) and its cell cycle-dependence have been described (Figure 26 A-D). Serum
starvation of breast and prostate cancer cells for 72-96 hours prevents cells from entering the S
phase of the cell cycle, arresting them in G1, during which time the amount of DNA is retained
and no new synthesis occurs (Chen et al., 2012; Elledge, 1996; Orlando et al., 2008). This could
be confirmed by the decrease in mRNA BCA2 levels observed in G1 cells (Figure 27A), further
suggesting that the BCA2 change may be regulated on the transcriptional level during the G1/S
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transition (Figure 26).

Furthermore, the protein synthesis inhibitor, cycloheximide, was

extremely potent in reducing BCA2 protein levels during S phase, affirming that the later
detected protein is as a result of new protein synthesis in S phase (Figure 27 B-C).
BCA2 was previously found to be present in the nucleus and cytoplasm. Figure 28 shows
that its cytoplasmic expression pattern, across a panel of breast cancer cell lines ranging in
degree of aggressiveness, tends to correlate with those that are triple negative and therefore more
aggressive (Figure 28A). Furthermore, in the less aggressive cell lines assessed (Figure 28B),
BCA2 is seen more equally disbursed amongst the nucleus and cytoplasm. We previously
investigated the transcriptional control of BCA2 by estrogen receptor and found it to be an
estrogen responsive gene, which may in part explain its increased nuclear expression seen in
these cell lines (Kona et al., 2012). From the fractionation experiments it may be that the
cytoplasmic form of BCA2 is the major contributor to its tumor promoting phenotype and the
predominant increase in cytoplasmic BCA2 observed during the S phase of the cell cycle (Figure
26) supports this idea. The decrease in nuclear (and some cytoplasmic) BCA2 during G1 is in
agreement with the fact that the nucleus is the site of DNA transcription, which is at a minimum
during this phase (Figure 29). Because BCA2 was shown to be a negative regulator of AMPK in
MDA MB 231 cells (Buac et al., 2013), and since most of the BCA2 present in this cell line is
cytoplasmic, it is again logical to conclude that it is this form of BCA2 that likely contributes to
the promotion of breast cancer cell growth. Along these lines, the previously reported (and
undesirable) increase in BCA2 protein levels in response to AMPK activators, metformin and
AICAR, does indeed appear to be more cytoplasm-related phenomenon (Figure 29B and C),
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again pointing to the possibility that this form of BCA2 is more active for its tumor promoting
activity than the nuclear expressed protein.
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Adenosine monophosphate-activated kinase (AMPK), a master regulator of cellular
energy homeostasis, has emerged as a promising molecular target in the prevention of breast
cancer, and phase II and III clinical trials using the FDA-approved, AMPK activating, antidiabetic drug metformin are promising in this regard, but the question of why metformin is
protective for some women but not others still remains. Breast Cancer Associated Gene 2
(BCA2/Rabring7/RNF115), a novel RING-finger ubiquitin E3 ligase, is overexpressed in >50%
of breast tumors. Herein, I hypothesized that BCA2 is an endogenous inhibitor of AMPK
activation in breast cancer cells and that BCA2 inhibition would therefore increase the efficacy
of metformin. My hypothesis is strongly supported by the finding that BCA2 overexpression
inhibited both basal and inducible Thr172 phosphorylation/activation of AMPK while BCA2specific siRNA enhanced pAMPK. Furthermore, the AMPK-suppressive function of BCA2
requires its E3 ligase-specific RING domain, suggesting that BCA2 targets a critical protein
controlling (de)phosphorylation of pAMPKfor degradation.

A large scale proteomics

analysis has revealed that PP2A and ITPR3 may be promising leads in this regard and should be
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further investigated in relation to AMPK activation by specifically CaMKK. Activation of
AMPK by metformin not only triggered growth a inhibitory signal, but also increased BCA2
protein (but not mRNA) levels, which correlated positively with activation of AKT and could be
curbed by an AMPK inhibitor, suggesting a potential feedback mechanism from AMPK to pAkt
to BCA2. Finally, BCA2 siRNA, or inhibition of its upstream stabilizing kinase AKT, increased
the growth-inhibitory effect of metformin in multiple breast cancer cell lines, supporting the
conclusion that BCA2 weakens metformin’s efficacy in breast cancer cells. My data therefore
suggests that metformin in combination with a BCA2 inhibitor may be a more effective breast
cancer treatment strategy than metformin alone. On this account, a first generation of “specific”
BCA2 inhibitors, as well as DSF analogs, is in existence and all compounds have been evaluated
for their cancer cell anti-proliferative effects and should be further tested in combination with
metformin. The studies performed in this dissertation provide new grounds for the development
of BCA2 as a novel anti-cancer drug target, and in addition, provide awareness for the potential
limitations metformin use in the clinic may have.
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